WO2021246471A1 - 高難度配列の効率的ペプチド縮合法 - Google Patents
高難度配列の効率的ペプチド縮合法 Download PDFInfo
- Publication number
- WO2021246471A1 WO2021246471A1 PCT/JP2021/021125 JP2021021125W WO2021246471A1 WO 2021246471 A1 WO2021246471 A1 WO 2021246471A1 JP 2021021125 W JP2021021125 W JP 2021021125W WO 2021246471 A1 WO2021246471 A1 WO 2021246471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- peptide
- compound
- resin
- fmoc
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 380
- 238000000034 method Methods 0.000 title claims description 180
- 238000009833 condensation Methods 0.000 title description 33
- 230000005494 condensation Effects 0.000 title description 33
- 150000001413 amino acids Chemical class 0.000 claims abstract description 403
- 150000001875 compounds Chemical class 0.000 claims abstract description 185
- 239000000654 additive Substances 0.000 claims abstract description 78
- 230000000996 additive effect Effects 0.000 claims description 73
- 239000003795 chemical substances by application Substances 0.000 claims description 62
- KPFBUSLHFFWMAI-HYRPPVSQSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-6-formyl-3-methoxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical group C1C[C@@H]2[C@](CCC(OC)=C3)(C)C3=C(C=O)C[C@H]2[C@@H]2CC[C@](OC(C)=O)(C(C)=O)[C@]21C KPFBUSLHFFWMAI-HYRPPVSQSA-N 0.000 claims description 43
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims description 38
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 21
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 14
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 12
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 11
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 10
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 9
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 7
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical group CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 6
- 238000006482 condensation reaction Methods 0.000 abstract description 74
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 35
- 235000001014 amino acid Nutrition 0.000 description 458
- 239000011347 resin Substances 0.000 description 337
- 229920005989 resin Polymers 0.000 description 337
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 269
- 238000006243 chemical reaction Methods 0.000 description 174
- 239000000243 solution Substances 0.000 description 167
- -1 Boc group Chemical group 0.000 description 162
- 230000015572 biosynthetic process Effects 0.000 description 127
- 238000003786 synthesis reaction Methods 0.000 description 125
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 95
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 89
- 238000011084 recovery Methods 0.000 description 70
- 238000010532 solid phase synthesis reaction Methods 0.000 description 61
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 56
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 55
- 239000002994 raw material Substances 0.000 description 53
- 125000000217 alkyl group Chemical group 0.000 description 50
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 50
- 125000001309 chloro group Chemical group Cl* 0.000 description 48
- 125000006239 protecting group Chemical group 0.000 description 48
- 238000011002 quantification Methods 0.000 description 44
- 239000002904 solvent Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 38
- 239000007790 solid phase Substances 0.000 description 38
- 238000004128 high performance liquid chromatography Methods 0.000 description 37
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 34
- 125000003277 amino group Chemical group 0.000 description 32
- 239000007858 starting material Substances 0.000 description 32
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 30
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 29
- 125000003710 aryl alkyl group Chemical group 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 238000003776 cleavage reaction Methods 0.000 description 25
- 230000007017 scission Effects 0.000 description 25
- 125000003118 aryl group Chemical group 0.000 description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 24
- 238000001308 synthesis method Methods 0.000 description 24
- 238000004364 calculation method Methods 0.000 description 23
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 23
- 125000001424 substituent group Chemical group 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- 125000000753 cycloalkyl group Chemical group 0.000 description 21
- 125000001072 heteroaryl group Chemical group 0.000 description 21
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 20
- 229910052739 hydrogen Inorganic materials 0.000 description 20
- 239000001257 hydrogen Substances 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 125000000623 heterocyclic group Chemical group 0.000 description 19
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 125000000304 alkynyl group Chemical group 0.000 description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 description 18
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
- 238000005406 washing Methods 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 238000010189 synthetic method Methods 0.000 description 14
- 125000002723 alicyclic group Chemical group 0.000 description 13
- 210000004899 c-terminal region Anatomy 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 230000002028 premature Effects 0.000 description 13
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 12
- 125000000524 functional group Chemical group 0.000 description 12
- 125000005647 linker group Chemical group 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 12
- YCXXXPZNQXXRIG-IBGZPJMESA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N(C)[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 YCXXXPZNQXXRIG-IBGZPJMESA-N 0.000 description 11
- 241000209094 Oryza Species 0.000 description 11
- 235000007164 Oryza sativa Nutrition 0.000 description 11
- 229940126214 compound 3 Drugs 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 235000009566 rice Nutrition 0.000 description 11
- 238000007363 ring formation reaction Methods 0.000 description 11
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
- 230000007547 defect Effects 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000003746 solid phase reaction Methods 0.000 description 10
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- 238000007086 side reaction Methods 0.000 description 9
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 229940126543 compound 14 Drugs 0.000 description 8
- 238000006345 epimerization reaction Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 238000010647 peptide synthesis reaction Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 7
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 7
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 7
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 7
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 7
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 7
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 7
- RVOBSFCFZOYWLO-MCYZKXFWSA-N 3-[4-[(2r,3r)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl]piperazin-1-yl]-2-methyl-1-phenylpropan-1-one;dihydrochloride Chemical compound Cl.Cl.C1CN([C@H]2[C@@H](CC3=CC=CC=C3C2)O)CCN1CC(C)C(=O)C1=CC=CC=C1 RVOBSFCFZOYWLO-MCYZKXFWSA-N 0.000 description 7
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 7
- 229940126639 Compound 33 Drugs 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 7
- KSPIYJQBLVDRRI-WDSKDSINSA-N N-methyl-L-isoleucine Chemical compound CC[C@H](C)[C@H](NC)C(O)=O KSPIYJQBLVDRRI-WDSKDSINSA-N 0.000 description 7
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 7
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 229940125851 compound 27 Drugs 0.000 description 7
- 229940127204 compound 29 Drugs 0.000 description 7
- 229940125877 compound 31 Drugs 0.000 description 7
- 229940125878 compound 36 Drugs 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical group 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000013076 target substance Substances 0.000 description 7
- BUJQSIPFDWLNDC-FQEVSTJZSA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N(C)[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 BUJQSIPFDWLNDC-FQEVSTJZSA-N 0.000 description 6
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 5
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
- GPDHNZNLPKYHCN-DZOOLQPHSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N/OC(=[N+](C)C)N1CCOCC1 GPDHNZNLPKYHCN-DZOOLQPHSA-N 0.000 description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 5
- 125000002393 azetidinyl group Chemical group 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 229940126208 compound 22 Drugs 0.000 description 5
- 229940125961 compound 24 Drugs 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- COCAUCFPFHUGAA-MGNBDDOMSA-N n-[3-[(1s,7s)-5-amino-4-thia-6-azabicyclo[5.1.0]oct-5-en-7-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SCC[C@@H]2C3)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 COCAUCFPFHUGAA-MGNBDDOMSA-N 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 4
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 4
- VUTZFAOGDXUYEJ-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-4-methylbenzene Chemical compound C1=CC(C)=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 VUTZFAOGDXUYEJ-UHFFFAOYSA-N 0.000 description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229940127007 Compound 39 Drugs 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 4
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 4
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 4
- 125000004103 aminoalkyl group Chemical group 0.000 description 4
- 238000006664 bond formation reaction Methods 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126086 compound 21 Drugs 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- OBOHMJWDFPBPKD-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 OBOHMJWDFPBPKD-UHFFFAOYSA-N 0.000 description 3
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 3
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 101100096578 Arabidopsis thaliana SQD2 gene Proteins 0.000 description 3
- 0 C*(C(C(*)**)C(OC)=O)N Chemical compound C*(C(C(*)**)C(OC)=O)N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- 239000003875 Wang resin Substances 0.000 description 3
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940127573 compound 38 Drugs 0.000 description 3
- 208000012839 conversion disease Diseases 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- 125000004149 thio group Chemical group *S* 0.000 description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 3
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- IQIOLCJHRZWOLS-XOBRGWDASA-N (2s,3s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N(C)[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 IQIOLCJHRZWOLS-XOBRGWDASA-N 0.000 description 2
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- ILROLYQPRYHHFG-UHFFFAOYSA-N 1-$l^{1}-oxidanylprop-2-en-1-one Chemical group [O]C(=O)C=C ILROLYQPRYHHFG-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- XZORQADPEUSNQJ-UHFFFAOYSA-N 2-(3-piperidin-4-yloxy-1-benzothiophen-2-yl)-5-[(1,3,5-trimethylpyrazol-4-yl)methyl]-1,3,4-oxadiazole Chemical compound CC1=NN(C)C(C)=C1CC1=NN=C(C2=C(C3=CC=CC=C3S2)OC2CCNCC2)O1 XZORQADPEUSNQJ-UHFFFAOYSA-N 0.000 description 2
- ZHKQIADIIYMFOZ-UHFFFAOYSA-N 2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)N(CC(O)=O)C)C3=CC=CC=C3C2=C1 ZHKQIADIIYMFOZ-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
- MVXAKOGJWVQPKC-UHFFFAOYSA-N 5-(3-ethynyl-5-fluorophenyl)-2-pyridin-2-yl-4,6,7,8-tetrahydro-[1,3]oxazolo[4,5-c]azepine Chemical compound FC1=CC(C#C)=CC(N2CC=3N=C(OC=3CCC2)C=2N=CC=CC=2)=C1 MVXAKOGJWVQPKC-UHFFFAOYSA-N 0.000 description 2
- LPWKFUVWWQYLOD-UHFFFAOYSA-N 9-(dimethylamino)-3-(4-methylphenyl)pyrido[2,3]thieno[2,4-d]pyrimidin-4-one Chemical compound C1=2C(N(C)C)=CN=CC=2SC(C2=O)=C1N=CN2C1=CC=C(C)C=C1 LPWKFUVWWQYLOD-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 239000005456 alcohol based solvent Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 125000000707 boryl group Chemical group B* 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000005252 haloacyl group Chemical group 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- JYRWUSXRTGACLY-UHFFFAOYSA-N tert-butyl 4-[[3-(4-methylsulfonylphenyl)-[1,2]oxazolo[4,5-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC2=C1ON=C2C1=CC=C(S(C)(=O)=O)C=C1 JYRWUSXRTGACLY-UHFFFAOYSA-N 0.000 description 2
- 125000001302 tertiary amino group Chemical group 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- YCXXXPZNQXXRIG-LJQANCHMSA-N (2r)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N(C)[C@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 YCXXXPZNQXXRIG-LJQANCHMSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- CYWWLVIEAOUXGW-FQEVSTJZSA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N([C@@H](CC(=O)OC(C)(C)C)C(O)=O)C)C3=CC=CC=C3C2=C1 CYWWLVIEAOUXGW-FQEVSTJZSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- YZBBUYKPTHDZHF-KNVGNIICSA-N (3R)-7,2'-dihydroxy-4'-methoxyisoflavanol Chemical compound OC1=CC(OC)=CC=C1[C@H]1C(O)C2=CC=C(O)C=C2OC1 YZBBUYKPTHDZHF-KNVGNIICSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- LENAVORGWBTPJR-UHFFFAOYSA-N (5-pyridin-3-ylfuran-2-yl)methanamine Chemical compound O1C(CN)=CC=C1C1=CC=CN=C1 LENAVORGWBTPJR-UHFFFAOYSA-N 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical group C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical group C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical group C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MNILDQSRDHCFJG-UHFFFAOYSA-N 3-oxa-8-azabicyclo[3.2.1]octane Chemical group C1OCC2CCC1N2 MNILDQSRDHCFJG-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical group O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- VPQUHMHAGBKYCF-NDOGSIMJSA-N CC(C)C[C@@H](C(OC(c1ccccc1)(c1ccc(C)cc1)c(cccc1)c1Cl)=O)N(C)C(OCC1c2ccccc2-c2ccccc12)=O Chemical compound CC(C)C[C@@H](C(OC(c1ccccc1)(c1ccc(C)cc1)c(cccc1)c1Cl)=O)N(C)C(OCC1c2ccccc2-c2ccccc12)=O VPQUHMHAGBKYCF-NDOGSIMJSA-N 0.000 description 1
- JLRXUVVYNRIAHD-VLQJHUBSSA-N CC(C)C[C@@H](C(OC(c1ccccc1)(c1ccc(C)cc1)c(cccc1)c1Cl)=O)N(C)C([C@@H](C(C)C)N(C)C(OCC1c(cccc2)c2-c2c1cccc2)=O)=O Chemical compound CC(C)C[C@@H](C(OC(c1ccccc1)(c1ccc(C)cc1)c(cccc1)c1Cl)=O)N(C)C([C@@H](C(C)C)N(C)C(OCC1c(cccc2)c2-c2c1cccc2)=O)=O JLRXUVVYNRIAHD-VLQJHUBSSA-N 0.000 description 1
- DLKZDDBLCOLFFU-SNTPOOIRSA-N CC(C)[C@@H](C(N(C)C(CC(OC(c1ccccc1)(c1ccc(C2CCCCCC2)cc1)c1ccccc1Cl)=O)C(N1CCCCC1)=O)=O)N(C)C(OCC1c2ccccc2-c2c1cccc2)=O Chemical compound CC(C)[C@@H](C(N(C)C(CC(OC(c1ccccc1)(c1ccc(C2CCCCCC2)cc1)c1ccccc1Cl)=O)C(N1CCCCC1)=O)=O)N(C)C(OCC1c2ccccc2-c2c1cccc2)=O DLKZDDBLCOLFFU-SNTPOOIRSA-N 0.000 description 1
- LBGVQAANDIPPAT-QFIPXVFZSA-N CC(C)[C@@H](C(N(C)CC(O)=O)=O)N(C)C(OCC1c2ccccc2-c2ccccc12)=O Chemical compound CC(C)[C@@H](C(N(C)CC(O)=O)=O)N(C)C(OCC1c2ccccc2-c2ccccc12)=O LBGVQAANDIPPAT-QFIPXVFZSA-N 0.000 description 1
- PUGLKOLZLZLUML-OTKZQKHGSA-N CC(C)[C@@H](C(OC(c1ccccc1)(c1ccc(C)cc1)c(cccc1)c1Cl)=O)N(C)C(OCC1c(cccc2)c2-c2c1cccc2)=O Chemical compound CC(C)[C@@H](C(OC(c1ccccc1)(c1ccc(C)cc1)c(cccc1)c1Cl)=O)N(C)C(OCC1c(cccc2)c2-c2c1cccc2)=O PUGLKOLZLZLUML-OTKZQKHGSA-N 0.000 description 1
- MPXOCDCVPUSGEM-YZYNAAERSA-N CC(C)[C@H](C)[C@@H](C(O)=O)N(C)C([C@@H](C(C)C)N(C)C(OCC1c2ccccc2-c2ccccc12)=O)=O Chemical compound CC(C)[C@H](C)[C@@H](C(O)=O)N(C)C([C@@H](C(C)C)N(C)C(OCC1c2ccccc2-c2ccccc12)=O)=O MPXOCDCVPUSGEM-YZYNAAERSA-N 0.000 description 1
- PFORSHGWLZLETQ-UHFFFAOYSA-N CN(C(CC(OC(c1ccccc1)(c1ccc(C2CCCCC2)cc1)c1ccccc1Cl)=O)C(N1CCCCC1)=O)C(OCC1c2ccccc2-c2c1cccc2)=O Chemical compound CN(C(CC(OC(c1ccccc1)(c1ccc(C2CCCCC2)cc1)c1ccccc1Cl)=O)C(N1CCCCC1)=O)C(OCC1c2ccccc2-c2c1cccc2)=O PFORSHGWLZLETQ-UHFFFAOYSA-N 0.000 description 1
- RAZDNNUJQWAATB-UHFFFAOYSA-N CN(C)C(CCC(OC)=O)=O Chemical compound CN(C)C(CCC(OC)=O)=O RAZDNNUJQWAATB-UHFFFAOYSA-N 0.000 description 1
- ICVVUGRWVWPDGU-UHFFFAOYSA-N CN(C=N)C(OCC1c2ccccc2-c2ccccc12)=O Chemical compound CN(C=N)C(OCC1c2ccccc2-c2ccccc12)=O ICVVUGRWVWPDGU-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical group CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 238000004617 QSAR study Methods 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000006323 alkenyl amino group Chemical group 0.000 description 1
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 description 1
- 125000005193 alkenylcarbonyloxy group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000005136 alkenylsulfinyl group Chemical group 0.000 description 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
- 125000005108 alkenylthio group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005130 alkyl carbonyl thio group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 125000006319 alkynyl amino group Chemical group 0.000 description 1
- 125000005095 alkynylaminocarbonyl group Chemical group 0.000 description 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
- 125000005088 alkynylcarbonylamino group Chemical group 0.000 description 1
- 125000005198 alkynylcarbonyloxy group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 description 1
- 125000005134 alkynylsulfinyl group Chemical group 0.000 description 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 1
- 125000005109 alkynylthio group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 description 1
- 125000005145 cycloalkylaminosulfonyl group Chemical group 0.000 description 1
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 description 1
- 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 description 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012351 deprotecting agent Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 description 1
- 229950006502 etelcalcetide Drugs 0.000 description 1
- 108091022127 etelcalcetide hydrochloride Proteins 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000000373 fatty alcohol group Chemical group 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 description 1
- 125000005204 heteroarylcarbonyloxy group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical group C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- XVQUOJBERHHONY-UHFFFAOYSA-N isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- YQCIWBXEVYWRCW-UHFFFAOYSA-N methane;sulfane Chemical compound C.S YQCIWBXEVYWRCW-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a method for producing a peptide compound using a condensation reaction.
- Patent Document 1 cyclization of peptides and N-alkylation of constituent amino acids, especially N-methylation, contribute to improvement of membrane permeability and metabolic stability (Non-Patent Documents 2 and 3), and intracellular. Findings and discussions on drug-like cyclic peptide structures, which are the key to migration and development of oral preparations, have been reported, and the importance of these structures in peptide drug discovery is increasing (Patent Document 1).
- Peptide synthesis is achieved by elongating to the desired sequence by forming an amide bond. More specific methods include a liquid phase method and a solid phase method (Non-Patent Document 4).
- the solid-phase method uses an atomic group linked to a polymer resin (resin for solid-phase synthesis) as a linker.
- 3) Cleavage of peptide from resin for solid-phase synthesis (resin removal step), and consists of (Non-Patent Documents 5 and 6).
- the solid-phase method is a two-layer reaction of a solid and a liquid, which comprises a step of contacting a solid solid-phase synthesis resin to which a target substance is bound with a liquid reaction solution in which a deprotection reaction and a reagent for a condensation reaction are dissolved. It is done in the system. Since the target peptide is bound to the solid-phase synthesis resin, only a cleaning operation of the solid-phase synthesis resin is incorporated between each step, and the solid-phase synthesis resin to which the target peptide is bound is excessive. Since it is possible to separate the reagent and impurities derived from the reagent, sequential elongation can be easily carried out.
- Fmoc group and Boc group are widely used as the protecting group for the amino group at the N-terminal of the amino acid main chain used in the solid phase method.
- resins for solid-phase synthesis are roughly classified by atomic groups that serve as linkers bonded to polymers used in the resins, and resins for solid-phase synthesis to which linker atomic groups containing trityl groups and benzyl groups are bonded are widely used. More specifically, CTC resin, Wang resin, SASRIN resin, Rink Amide resin and the like are typical.
- the resin removal step is mainly carried out under acidic conditions, but the ease of resin removal is determined by the stability of the linker atomic group to acid.
- the resin removal reaction of a peptide from a CTC resin capable of binding a peptide using a trityl group as a linker can also be carried out with a weakly acidic reagent.
- strong acid conditions are applied to the resin removal reaction of the peptide from Wang resin, which can bind the peptide using a benzyl group as a linker (Non-Patent Document 6).
- the amino group of the amino acid or the peptide and the carboxyl group of the amino acid in which the newly introduced N-terminal amino group is protected are dehydrated regardless of the solid phase method or the liquid phase method. It consists of repeating a condensation step of condensing and a deprotection step of removing the newly introduced protective group of the amino group at the N-terminal. If the condensation reaction is not achieved and / or the competition for side reactions accumulates in this repeating step, the peptide having the target sequence is defective or added with an amino acid, and the peptide has the target sequence. Yield and / or purity may decrease.
- Non-Patent Document 6 there is a report that it is better to apply the same conditions again than to prolong the reaction as a countermeasure against the unachieved reaction of the condensation reaction.
- the unreacted N-terminal amino group for which the desired condensation reaction has not been achieved is deleted by reacting with the newly introduced N-terminal amino group protected amino acid (also referred to as the amino acid in the following sequence).
- the body may arise.
- an acylating agent exemplified by acetic anhydride or benzoyl chloride is reacted in the presence of pyridine to generate an unreacted N-terminal amino group in which the desired condensation reaction has not been achieved. Capping with an acylating agent can prevent undesired sequence elongation (Non-Patent Document 6).
- the peptide when CTC resin is used, the peptide can be de-resined under mild weak acid conditions.
- peptides with protecting groups that are easily removed under acidic conditions can be selectively deresinized without deprotecting the protecting groups, and are protected by the desired protecting groups. It is useful for the production of the peptide (Non-Patent Document 7).
- the peptide in the solid-phase synthesis of the peptide using the CTC resin, the peptide can be removed from the CTC resin under mild conditions.
- Non-Patent Document 8 Gly, Pro, and Leu are exemplified as amino acids supported on CTC resin, and the stability of the amino acid-supported CTC resin during the condensation reaction with Fmoc-Gly-OH is shown for each of them. It is being investigated.
- Non-Patent Document 9 the condensation conditions of DIC / K-Oxyma significantly improved the yield compared to DIC / Oxyma, and the partial sequence of myelin basic protein (MBP) was obtained with the same or higher purity. There is a report that it was given (Non-Patent Document 9).
- the solid-phase peptide synthesis method using K-Oxyma is concerned about the increase in the epimerization rate at the time of scale-up and the decrease in purity in view of the lengthening of the reagent charging time associated with the scale-up.
- TOTU is used as a DIC substitute reagent (Non-Patent Document 10), but since it requires a reaction under basic conditions, there is a possibility of epimerization. Furthermore, since TOTU is an expensive reagent, it causes an increase in manufacturing cost and is not preferable. Further, in this document, in addition to the decrease in yield due to premature cleavage, the case of decrease in purity due to the by-product of an overstretched product is also described. That is, when Gly-OCTC in which Gly was supported on a resin for solid-phase synthesis was used as a starting material and an extension reaction of Fmoc amino acid was carried out using DIC / HOBt, a by-product having the sequence of Gly-Gly-OCTC was produced. It is stated that it was obtained. It is considered that this by-product was obtained by deresinating the Gly residue carried on the CTC resin during the extension reaction of the second amino acid and condensing it with the unreacted Gly-OCTC.
- Non-Patent Document 11 A method of using Oxyma as an additive for the amino acid condensation reaction is known. It has been described that when Oxyma is used as an additive, epimerization can be suppressed and the acylation rate is improved (Non-Patent Document 11).
- Patent Documents 1, 2, 3, 4, 5, and 6, which will be described later, and Non-Patent Document 12 various condensing agents and additives are used in the production of peptides by a condensation reaction.
- these documents do not describe the problems in the peptide condensation reaction, which are exemplified in the premium cleavage.
- Patent Document 1 relates to a novel peptide cyclization method, a novel peptide, and a library containing them, which provides an effective drug discovery method for tough targets, which has been difficult in the past.
- reagents are used in a specific ratio, but there is no description that the reaction conditions are set for the purpose of solving the problem peculiar to the condensation reaction of the peptide exemplified in the premium cleavage.
- Patent Document 2 a solid-phase synthesis method for peptides using CTC resin is carried out.
- the past production methods were affected by the atypical conformation associated with peptide chain elongation, which led to the progress of side reactions, and the improvement of the production method to solve this problem. Is only mentioned.
- the amino acids that make up the peptide do not contain unnatural amino acids such as N-substituted amino acids, there are descriptions of defects such as the failure to reach the condensation reaction due to a special amino acid structure, and issues related to defects in the condensation reaction. There is no description to solve the problem.
- Patent Document 3 solid-phase synthesis of a peptide using Rink's amide resin was previously subjected to a pretreatment step (also referred to as preactivation) for converting a C-terminal amino acid into an active ester, and then a pretreatment step was performed.
- the method is to add a resin for solid phase synthesis to the reaction solution.
- Patent Document 3 merely describes the production of a peptide having a specific sequence (AMG416 or a salt thereof), and is exemplified by a condensation reaction between amino acids having a large steric hindrance, which is an extension reaction of a low-reactivity amino acid. The improvement of is not disclosed.
- Patent Document 4 describes the improvement of the de-Fmocification reaction. However, the problems peculiar to the condensation reaction of peptides exemplified by premium cleavage are not described. In addition, since the amino acids used in this document are excessively required, they are not suitable for producing peptides containing unnatural amino acids represented by N-substituted amino acids, which are difficult to obtain as compared with natural amino acids.
- Patent Document 5 a gentle deresining process method that avoids damage to peptides containing N-substituted amino acids that are unstable to acid in solid-phase synthesis and a side chain functional group protecting group that is not removed in this deresinating step Is described.
- the problems peculiar to the condensation reaction of peptides exemplified by premium cleavage are not described.
- Patent Document 6 describes a method for treating a deprotecting agent in the deprotecting step of solid-phase synthesis.
- the problems peculiar to the condensation reaction of peptides exemplified by premium cleavage are not described.
- Non-Patent Document 12 describes a solid-phase method using an alternative solvent having high environmental friendliness without using DMF or DCM, which are generally used in the solid-phase method.
- the condensation reaction of amino acids with large steric hindrance, such as N-substituted amino acids, ⁇ , ⁇ -di-substituted amino acids, or ⁇ -branched amino acids is not described.
- the present inventors applied the condensation reaction conditions of the solid-phase method, which are widely used in conventional peptide synthesis, to the production of peptide compounds containing unnatural amino acids using CTC resin. Faced with the problems of significant yield and purity reduction. Such defects during the condensation reaction include not only the condensation reaction between natural ⁇ -amino acids described in Non-Patent Documents 8, 9 and 10, but also N-substituted amino acids and amino acids having a branch at the ⁇ position of the side chain ( ⁇ ). -It was found to be remarkable in the sequence, which is exemplified by (also called a branched amino acid), which has a large steric disorder and poor reactivity of the condensation reaction.
- the present invention can suppress premature cleavage in the solid-phase synthesis method of peptides, especially in the step of condensation reaction, and can also suppress side reactions such as unreached reaction and competition for epimerization, and can be easily obtained.
- the present inventors mainly condense a second amino acid with a first amino acid in which an N-substituted amino acid is carried on a solid-phase synthesis resin to obtain a two-residue peptide.
- the obtained 1-residue + 1-residue synthesis was enthusiastically investigated.
- DIC carbodiimide compound exemplified by DIC
- Oxyma an N-hydroxy compound exemplified by Oxyma
- the amino acids to be introduced, the condensing agent, and the additive are used. It is a general-purpose condition to use the same equality ratio.
- a sequence in which the amidation reaction is difficult to proceed due to a large steric disorder specifically, an N-substituted amino acid, an ⁇ , ⁇ -di-substituted amino acid, a ⁇ -branched amino acid, or an amino acid having a bulky side chain is condensed.
- an N-substituted amino acid, an ⁇ , ⁇ -di-substituted amino acid, a ⁇ -branched amino acid, or an amino acid having a bulky side chain is condensed.
- the method of the present invention can produce a peptide compound having a target sequence in one aspect thereof. Furthermore, it has been found that the method of the present invention can carry out the desired condensation reaction in high yield in one aspect thereof. Furthermore, it has been found that the method of the present invention can suppress a side reaction exemplified by epimerization in one aspect thereof. Furthermore, it has been found that the method of the present invention can obtain the desired peptide compound in high yield and high purity because the amidation reaction proceeds at a sufficient conversion rate in one aspect thereof.
- the additive is effective to change the molar ratio of the additive to the amino acid or peptide added to the N-terminus (ie, the second amino acid or peptide), especially the amino acid or peptide added to the N-terminus.
- the N-terminus ie, the second amino acid or peptide
- it is better to use less additives than peptides.
- it is also effective to change the molar ratio of the condensing agent, and it is particularly good to use an excessive amount of the condensing agent for the amino acid or peptide added to the N-terminal.
- changing the molar ratio of both the condensing agent and the additive is more effective.
- the amidation reaction proceeds at a sufficient conversion rate not only in the condensation of an amino acid or peptide having a large steric disorder but also in the condensation reaction of an amino acid or peptide having a small steric disorder, and the yield and purity are high. It has been found that the desired peptide compound can be obtained.
- the present invention includes the following in a specific non-limiting aspect.
- a method for producing a peptide compound which comprises a step of condensing a first amino acid or peptide and a second amino acid or peptide in the presence of an additive and a condensing agent to obtain a condensate. The method described above, wherein the number of moles of the additive is less than the number of moles of the second amino acid or peptide.
- the molar ratio of the additive to the second amino acid or peptide is 0.8 or less.
- the molar ratio of the second amino acid or peptide to the first amino acid or peptide is 1 to 2, and the molar ratio of the additive to the second amino acid or peptide is 0.7 or less, [1] to [. 5]
- the molar ratio of the second amino acid or peptide to the first amino acid or peptide (first molar ratio) is 2 or more, and the molar ratio of the additive to the second amino acid or peptide is the first.
- P 11 is hydrogen or C 1 -C 6 alkyl
- R 12 is hydrogen, CONR 12A R 12B , COOR 12c , C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 7 -C 14 aralkyl, 5-10 membered heteroaryl C 1- C 6 alkyl, protected 5-10 membered heteroaryl C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, protected C 1 -C 6 hydroxyalkyl, C 1 -C 6 carboxy Alkyl, Protected C 1- C 6 Carboxyalkyl, C 1 -C 6 Aminoalkyl, Protected C 1 -C 6 Aminoalkyl, C 1 -C 6 Alkthio C 1 -C 6 Alkyl, or P 11 and R 12 Formed a 4- to 7-membered saturated heterocycle with the nitrogen atom to which P 11 is bonded and the carbon atom to which R 12 is bonded.
- Q 12 is hydrogen, or C 1- C 6 alkyl and R 12A and R 12B are independently C 1- C 4 alkyl, or R 12A and R 12B are nitrogen atoms to which they are attached. Together with form a 4- to 8-membered ring, which may contain one or more additional heteroatoms, L 11 is single bond or -CH 2-
- R 13 means the bonding point with the resin for solid phase synthesis, and the first peptide.
- R 13 means the binding point with the adjacent amino acid.
- the first amino acid, or the N-terminal amino acid of the first peptide, and / or the C-terminal amino acid of the first peptide are MeAsp-pip, MeAsp-aze, MeAsp-pyrro, MeAsp-mor, MeAsp.
- the second amino acid, or the C-terminal amino acid of the second peptide has an ⁇ , ⁇ -di-substituted amino acid, ⁇ -branched amino acid, N-alkyl amino acid, or other side chain having 2 or more carbon atoms.
- R 23 means the binding point with the protective group of the amino group
- the amino acid at the C-terminal of the second peptide is the amino acid of the formula (2A).
- R 23 means a binding point with an adjacent amino acid.
- ⁇ -branched amino acids are MeVal, D-MeVal, Val, Ile, MeIle, MeChg, Chg, MeGly (cPent), Gly (cPent), MeGly (cBu), Gly (cBu), MeGly (cPr), The method according to [30], which is Gly (cPr), MeThr (tBu), or Thr (tBu).
- R 25 means a binding point with an adjacent amino acid.
- ⁇ , ⁇ -di-substituted amino acids are Aib, (Me) Abu, (Me) Leu, (Me) Algly, (Me) Phe, (Me) Phe (3-I), 1-ACPrC, cVal, The method according to [32], which is cLeu, cHex, or Athpc. [34] The method according to any one of [1] to [33], wherein the second amino acid or the C-terminal amino acid of the second peptide is an N-alkyl amino acid.
- N-alkyl amino acids are MeAsp-pip, MeAsp-aze, MeAsp-pyrro, MeAsp-mor, MeAsp-mor (26-bicyc), MeAsp-OtBu, D-3-MeAbu, bMeAla, MeGly, MeAla, MeLeu, MePhe, Aze (2), Pro, MeAsp-NMe2, MeVal, MeIle, MeChg, MeGly (cPent), MeGly (cBu), MeGly (cPr), MeThr (tBu), D-MeVal, MeTrp (Boc), The method according to [34], which is MeThr (Bzl), MeGlu (OtBu), MeLys (Boc), or MeMet.
- a peptide compound containing a sequence having poor reactivity in a condensation reaction can be efficiently produced. Specifically, it is possible to improve the productivity including the improvement of the yield and the purity of the peptide compound. That is, in one aspect of the method of the present invention, not only the inhibitory effect of premature cleavage, but also a peptide compound containing an amino acid sequence in which the condensation reaction is not achieved when the conventional method is applied, and an amino acid sequence in which epimerization is antagonized. Since a peptide compound containing the above can also be produced, the yield and / or purity of the peptide compound can be improved.
- side reactions can be minimized even if the condensation reaction is prolonged, and / or the amino acid or peptide added to the N-terminal is used in the minimum amount. Since the reaction can be completed, the amount used can be reduced. In the method of the present invention, the reaction is completed even if the amount of the reagent is reduced, so that it is not necessary to use an excessive amount of the reagent or to carry out double coupling in which the same conditions are repeated, unlike the conventional method. As a result, the amount of reagent can be minimized even when amino acids and peptides that are difficult to amidate are used. This is a particularly suitable method for the synthesis of peptide compounds containing expensive and rare unnatural amino acid residues.
- the method of the present invention reduces the solvent at the time of condensation, has a large reaction promoting effect when the reaction is carried out at a high concentration, and can reduce the amount of amino acids used, as compared with the conventional method.
- the amount of solvent required for cleaning the reagent after condensation can be reduced.
- the present invention solves a problem peculiar to the condensation reaction of an amino acid or peptide carried on a trityl resin (for example, CTC resin) and an amino acid or peptide to be extended, which is exemplified by the condensation reaction of a peptide exemplified by premium cleavage.
- a trityl resin for example, CTC resin
- an amino acid or peptide to be extended which is exemplified by the condensation reaction of a peptide exemplified by premium cleavage.
- the amino acid or peptide carried on the resin can be sufficiently consumed, the starting material can be efficiently converted into the target product.
- MeAsp (OH) -pip is an amino acid having the following structure in which the Fmoc group is removed from Fmoc-MeAsp (OH) -pip in the table below.
- the structure of the amino acid residue MeAsp-pip is also obvious to those skilled in the art.
- halogen atom examples include F, Cl, Br or I.
- alkyl is a monovalent group derived from an aliphatic hydrocarbon by removing one arbitrary hydrogen atom, and refers to a hetero atom (an atom other than carbon and a hydrogen atom) in the skeleton. ) Or unsaturated carbon-carbon bonds and have a subset of hydrocarbyl or hydrocarbon group structures containing hydrogen and carbon atoms.
- Alkyl includes not only linear ones but also branched chain ones. Specifically, the alkyl is an alkyl having 1 to 20 carbon atoms (C 1 -C 20 , hereinafter "C p -C q " means that the number of carbon atoms is p to q).
- C 1- C 10 alkyl more preferably C 1- C 6 alkyl.
- alkyl specifically, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, isobutyl (2-methylpropyl), n-pentyl, s-pentyl (1-pentyl).
- Methylbutyl t-pentyl (1,1-dimethylpropyl), neopentyl (2,2-dimethylpropyl), isopentyl (3-methylbutyl), 3-pentyl (1-ethylpropyl), 1,2-dimethylpropyl, 2 -Methylbutyl, n-hexyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1,1,2,2-tetramethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl , 1,3-Dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl and the like.
- alkenyl is a monovalent group having at least one double bond (two adjacent SP 2 carbon atoms). Depending on the double bond and the arrangement of the substitutions (if any), the geometry of the double bond can be an entomen (E) or tuzanmen (Z), cis or trans arrangement.
- Alkenyl includes not only linear ones but also branched chain ones. Examples of the alkenyl include C 2- C 10 alkenyl and more preferably C 2- C 6 alkenyl, and specific examples thereof include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl and 2-butenyl. (Including cis and trans), 3-butenyl, pentenyl, 3-methyl-2-butenyl, hexenyl and the like can be mentioned.
- alkynyl is a monovalent group having at least one triple bond (two adjacent SP carbon atoms). Alkynes include not only linear ones but also branched chain ones.
- the alkynyl is preferably C 2- C 10 alkynyl, more preferably C 2- C 6 alkynyl, and specifically, for example, ethynyl, 1-propynyl, propargyl, 3-butynyl, pentynyl, hexynyl, 3-phenyl.
- cycloalkyl means a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, and includes a monocyclic ring, a bicyclo ring, and a spiro ring.
- Preferred examples of the cycloalkyl include C 3- C 8 cycloalkyl, and specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo [2.2.1] heptyl, and spiro [. 3.3] Heptyl and the like.
- aryl means a monovalent aromatic hydrocarbon ring, preferably C 6- C 10 aryl. Specific examples of the aryl include phenyl, naphthyl (eg, 1-naphthyl, 2-naphthyl) and the like.
- heterocyclyl means a non-aromatic cyclic monovalent group containing 1 to 5 heteroatoms in addition to a carbon atom.
- the heterocyclyl may have double and / or triple bonds in the ring, and the carbon atom in the ring may be oxidized to form a carbonyl, which may be a monocyclic or fused ring.
- the number of atoms constituting the ring is preferably 4 to 10 (4 to 10-membered heterocyclyl), more preferably 4 to 7 (4 to 7-membered heterocyclyl).
- heterocyclyl examples include azetidinyl, oxetanyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, tetrahydropyranyl, tetrahydropyrimidyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrazoridinyl, and imidazolinyl.
- heteroaryl means an aromatic cyclic monovalent group containing 1 to 5 heteroatoms in addition to a carbon atom.
- the ring may be a single ring, a fused ring with another ring, or may be partially saturated.
- the number of atoms constituting the ring is preferably 5 to 10 (5 to 10-membered heteroaryl), and more preferably 5 to 7 (5 to 7-membered heteroaryl).
- heteroaryl examples include frills, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridadinyl, pyrazinyl, triazinyl, benzofuranyl, and benzothienyl.
- alkoxy means an oxy group to which the "alkyl” of the above definition is bonded, and C 1- C 6 alkoxy is preferable. Specific examples of the alkoxy include methoxy, ethoxy, 1-propoxy, 2-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, pentyloxy, 3-methylbutoxy and the like.
- alkylthio means a thio group to which the "alkyl” as defined above is attached, preferably C 1- C 6 alkylthio.
- Specific examples of the alkoxy include methylthio, ethylthio, 1-propylthio, 2-propylthio, n-butylthio, i-butylthio, s-butylthio, t-butylthio and the like.
- amino means -NH 2 in a narrow sense and -NRR'in a broad sense, where R and R'are independent of hydrogen, alkyl, alkenyl, alkynyl, cyclo. Selected from alkyl, heterocyclyl, aryl, or heteroaryl, or R and R'form a ring together with the nitrogen atom to which they are attached.
- Preferred aminos include -NH 2 , mono-C 1- C 6 alkyl aminos, di C 1- C 6 alkyl aminos, 4- to 8-membered cyclic aminos and the like.
- acyl alkanoyl
- alkyl preferably C 1- C 6 acyl, more preferably C 2 -C 4 Acyl is mentioned.
- Specific examples of the acyl include formyl, acetyl, propionyl, butanoyl and the like.
- cycloalkoxy means an oxy group to which the "cycloalkyl” as defined above is bound, and preferably C 3- C 8 cycloalkoxy. Specific examples of cycloalkoxy include cyclopropoxy, cyclobutoxy, cyclopentyloxy and the like.
- alkylsulfonyl means a sulfonyl group to which the "alkyl” as defined above is attached, preferably C 1- C 6 alkyl sulfonyl. Specific examples of the alkyl sulfonyl include methyl sulfonyl and the like.
- hydroxyalkyl means a group in which one or more hydrogens of the above-defined “alkyl” are substituted with hydroxyl groups, and C 1- C 6 hydroxyalkyl is preferable.
- Specific examples of the hydroxyalkyl include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, 5-hydroxypentyl and the like.
- carboxyalkyl means one or more hydrogen-substituted groups of "alkyl” as defined above, preferably C 1- C 6 carboxyalkyl. Specific examples of the carboxyalkyl include carboxymethyl, 1-carboxyethyl, 2-carboxyethyl and the like.
- protected carboxylalkyl means a group in which the carboxyl group contained in the above-defined “carboxyalkyl” is protected by an arbitrary protecting group.
- a protective group for a carboxyl group a methyl group, an ethyl group, a t-Bu group, a benzyl group, a trityl group, a cumyl group, a methoxytrityl group, a 2- (trimethylsilyl) ethyl group, 2,2,2-trichloro Examples thereof include an ethyl group and an allyl group.
- aminoalkyl means a group in which one or more hydrogens of the above-defined “alkyl” are substituted with the above-defined “amino", preferably C 1- C 6 aminoalkyl.
- Specific examples of the aminoalkyl include 1-pyridylmethyl, 2- (1-piperidyl) ethyl, 3- (1-piperidyl) propyl, 4-aminobutyl and the like.
- protected aminoalkyl means a group in which the amino group contained in the above-defined “aminoalkyl” is protected by an arbitrary protecting group.
- amino-protecting groups include Fmoc, Boc, Cbz, Alloc, Teoc, trifluoroacetyl, pentafluoropropionyl, phthaloyl, tosyl, 2-nitrobenzenesulfonyl, 4-nitrobenzenesulfonyl, 2,4-dinitrobenzenesulfonyl. And so on.
- haloalkyl means a group in which one or more hydrogens of "alkyl” as defined above are substituted with halogen, preferably C 1- C 6 haloalkyl, preferably C 1- C 6 fluoroalkyl. Is more preferable.
- haloalkyl for example, difluoromethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3-difluoropropyl, 4,4-difluorobutyl, 5,5 -For example, difluoropentyl.
- alkoxyalkyl means a group in which one or more hydrogens of "alkyl” in the above definition are substituted with “alkoxy” in the above definition, and C 1 -C 6 alkoxy C 1- C. 6- alkyl is preferred, with C 1- C 6 alkoxy C 1- C 2 alkyl being more preferred.
- Specific examples of alkoxyalkyl include methoxymethyl, ethoxymethyl, 1-propoxymethyl, 2-propoxymethyl, n-butoxymethyl, i-butoxymethyl, s-butoxymethyl, t-butoxymethyl, and pentyloxymethyl. Examples thereof include 3-methylbutoxymethyl, 1-methoxyethyl, 2-methoxyethyl and 2-ethoxyethyl.
- alkylthioalkyl means a group in which one or more hydrogens of "alkyl” as defined above are substituted with “alkylthio” as defined above, C 1- C 6 alkylthio C 1- C. 6- alkyl is preferred, and C 1- C 6- alkylthio C 1- C 2 alkyl is more preferred.
- alkylthioalkyl for example, methylthiomethyl, ethylthiomethyl, 1-propylthiomethyl, 2-propylthiomethyl, n-butylthiomethyl, i-butylthiomethyl, s-butylthiomethyl, t-butyl
- alkylthioalkyl for example, methylthiomethyl, ethylthiomethyl, 1-propylthiomethyl, 2-propylthiomethyl, n-butylthiomethyl, i-butylthiomethyl, s-butylthiomethyl, t-butyl
- alkylthioalkyl for example, methylthiomethyl, ethylthiomethyl, 1-propylthiomethyl, 2-propylthiomethyl, n-butylthiomethyl, i-butylthiomethyl, s-butylthiomethyl, t-butyl
- examples thereof include thiomethyl, 1-methylthioeth
- haloalkoxy means a group in which one or more hydrogens of "alkoxy” as defined above are substituted with halogen, and C 1- C 6 haloalkoxy is preferable.
- Specific examples of the haloalkoxy include difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy and the like.
- haloacyl means a group in which a carbonyl group is bonded to the "haloalkyl", preferably C 2- C 6 haloacyl, more preferably C 2- C 4 haloacyl.
- haloacyl include trifluoroacetyl, trichloroacetyl, pentafluoropropionyl, 2,3,3,3-tetrafluoro-2- (trifluoromethyl) propionyl, 3,3,3-trifluoro-2-. (Trifluoromethyl) propionyl and the like are exemplified.
- cycloalkylalkyl means a group in which one or more hydrogens of "alkyl” as defined above are substituted with “cycloalkyl” as defined above, C 3- C 8 cycloalkyl C. 1- C 6 alkyl is preferred, C 3 -C 6 cycloalkyl C 1 -C 2 alkyl is more preferred. Specific examples of the cycloalkylalkyl include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl and the like.
- cycloalkoxyalkyl means a group in which one or more hydrogens of "alkyl” as defined above are substituted with “cycloalkoxy” as defined above, and C 3- C 8 cycloalkoxy C.
- 1- C 6 alkyl is preferred, and C 3 -C 6 cycloalkoxy C 1- C 2 alkyl is more preferred.
- Specific examples of the cycloalkoxyalkyl include cyclopropoxymethyl and cyclobutoxymethyl.
- alkylsulfonylalkyl means a group in which one or more hydrogens of "alkyl” as defined above are substituted with “alkylsulphonyl” as defined above, C 1- C 6 alkylsulfonylC. 1- C 6 alkyl is preferred, C 1 -C 6 alkyl sulfonyl C 1 -C 2 alkyl is more preferred. Specific examples of the alkylsulfonylalkyl include methylsulfonylmethyl and 2- (methylsulfonyl) ethyl.
- aralkyl (arylalkyl) means a group in which at least one hydrogen atom of "alkyl” as defined above is substituted with "aryl” as defined above, preferably C 7- C 14 aralkyl. , C 7 -C 10 Aralkill is more preferred.
- Specific examples of the aralkyl include benzyl, phenethyl, 3-phenylpropyl and the like.
- heteroarylalkyl means a group in which at least one hydrogen atom of "alkyl” as defined above is substituted with “heteroaryl” as defined above, and a 5- to 10-membered heteroaryl C 1-.
- C 6 alkyl is preferred, and 5-10 membered heteroaryl C 1- C 2 alkyl is more preferred.
- Specific examples of the heteroarylalkyl include 3-thienylmethyl, 4-thiazolylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2- (2-pyridyl) ethyl, and 2- (3-pyridyl).
- protected heteroarylalkyl means a group in which one or more functional groups contained in the "heteroarylalkyl” as defined above, for example, an amino group is protected by any protecting group. do.
- protecting group include Fmoc, Boc, Cbz, Alloc, Teoc, trifluoroacetyl, pentafluoropropionyl, phthaloyl, tosyl, 2-nitrobenzenesulfonyl, 4-nitrobenzenesulfonyl, 2,4-dinitrobenzenesulfonyl and the like. Be done.
- the "carboxyl group protecting group” includes an alkyl ester type protecting group, a benzyl ester type protecting group, a substituted alkyl ester type protecting group and the like. Specifically, as a protective group for a carboxyl group, a methyl group, an ethyl group, a t-Bu group, a benzyl group, a trityl group, a cumyl group, a methoxytrityl group, a 2- (trimethylsilyl) ethyl group, 2,2,2-trichloro Examples thereof include an ethyl group and an allyl group.
- amino group protecting group includes a carbamate type protecting group, an amide type protecting group, an imide type protecting group, a sulfonamide type protecting group and the like.
- amino-protecting groups include Fmoc, Boc, Cbz, Alloc, Teoc, trifluoroacetyl, pentafluoropropionyl, phthaloyl, tosyl, 2-nitrobenzenesulfonyl, 4-nitrobenzenesulfonyl, 2,4-dinitrobenzenesulfonyl. Etc. are exemplified.
- the "alicyclic ring” in the present specification means a non-aromatic hydrocarbon ring.
- the alicyclic ring may have an unsaturated bond in the ring or may be a polycyclic ring having two or more rings. Further, the carbon atoms constituting the ring may be oxidized to form a carbonyl.
- the alicyclic ring is preferably a 3- to 8-membered alicyclic ring, and specific examples thereof include a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a cyclooctane ring, and a bicyclo [. 2.2.1] Heptane ring and the like can be mentioned.
- saturated heterocycle means a non-aromatic heterocycle containing 1 to 5 heteroatoms in addition to a carbon atom and no double or triple bonds in the ring. do.
- the saturated heterocycle may be a monocyclic ring, or may form a fused ring with another ring, for example, an aromatic ring such as a benzene ring.
- the saturated heterocycle preferably includes a 4- to 7-membered saturated heterocycle, and specific examples thereof include an azetidine ring, an oxazolidine ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a thiomorpholin ring, a pyrrolidine ring, and 4-oxo.
- peptide refers to a peptide in which one or more natural and / or unnatural amino acids are linked by an amide bond and / or an ester bond.
- the peptide is preferably a peptide containing 1 to 15 amino acid residues, and more preferably a peptide consisting of 5 to 12 amino acid residues.
- the "peptide compound” in the present specification is not particularly limited as long as it is a peptide compound in which a natural amino acid and / or an unnatural amino acid is linked by an amide bond or an ester bond, but is preferably 5 to 30 residues, more preferably 8. It is a peptide compound having up to 15 residues, more preferably 9 to 13 residues.
- the peptide compound synthesized in the present invention preferably contains at least 3 N-substituted amino acids in one peptide, and more preferably contains at least 5 or more N-substituted amino acids. These N-substituted amino acids may be present continuously or discontinuously in the peptide compound.
- the peptide compound in the present invention may be linear or cyclic, and a cyclic peptide compound is preferable.
- cyclic peptide compound in the present specification is a cyclic peptide compound that can be obtained by cyclizing the N-terminal side group and the C-terminal side group of the linear peptide compound. Cycling is carbon-nitrogen bond cyclization such as amide bond, carbon-oxygen bond cyclization such as ester bond or ether bond, carbon-sulfur cyclization such as thioether bond, carbon-carbon bond. It may be in any form, such as cyclization by cyclization by, or cyclization by construction of a heterocycle.
- cyclization via a covalent bond such as an amide bond or a carbon-carbon bond is preferable, and cyclization via an amide bond between the carboxyl group of the side chain and the amino group of the N-terminal main chain is more preferable.
- the positions of the carboxyl group, amino group and the like used for cyclization may be those on the main chain or those on the side chains, and are not particularly limited as long as they are in cyclizable positions.
- Cyclication of a peptide compound means forming a cyclic moiety containing 4 or more amino acid residues.
- the number of amino acids contained in the cyclic portion of the cyclic peptide compound in the present specification is not particularly limited, but 4 to 20 residues, 5 to 15 residues, and 6 to 13 residues are exemplified.
- Methods for converting linear peptide compounds to cyclic peptide compounds include Comprehensive Organic Transformations, A Guide to Functional Group Preparations, 3rd Edition, (R. C. Larock), or March's Advanced Organic Chemistry: Reactions, Mechanisms, and It can be carried out by performing an intramolecular bond-forming reaction by the method described in Structure, 7th Edition, (M.B. Smith, J.
- the bond formation reaction used C (O) -N bonds formed from carboxylic acids and amines, COC bonds using oxygen atoms, C (O) -O bonds, C (S) -O bonds, and sulfur atoms.
- C (O) -S bond, C (S) -S bond, CSSC bond, CSC bond, CS (O) -C bond, CS (O2) -C bond, CNC bond using nitrogen atom, C NC Examples thereof include a bond, an NC (O) -N bond, an NC (S) N bond, and a C (S) -N bond.
- reaction such as Suzuki reaction, Heck reaction, Sonogashira reaction and the like, which are catalyzed by transition metals to form C-C bonds.
- An oxidation reaction or a reduction reaction is exemplified as a functional group conversion reaction further carried out after the bond formation reaction. Specifically, a reaction of oxidizing a sulfur atom to a sulfoxide group or a sulfone group is exemplified. Further, among carbon-carbon bonds, a reduction reaction in which a triple bond or a double bond is reduced to a double bond or a single bond is exemplified.
- a peptide bond forms a closed ring structure, but the side chains of the two amino acids, the side chain and the main chain, etc. form a covalent bond between the two amino acids. May be done.
- one or more means one or two or more numbers.
- the term means the number from one to the maximum number of substituents that group allows. Specific examples of "one or more” include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and / or larger numbers.
- the "resin for solid phase synthesis” is not particularly limited as long as it can be used for the synthesis of peptide compounds by the solid phase method.
- Specific examples of such a resin for solid phase synthesis include CTC resin, NovaSyn TGT resin (TGT resin), Wang resin, SASRIN resin, trityl chloride resin (Trt resin), and 4-methyltrityl chloride resin (Mtt).
- Resin ), 4-methoxytrityl chloride resin (Mmt resin), etc., which can be removed under acidic conditions.
- the resin can be appropriately selected according to the functional group of the amino acid used.
- a carboxyl group main chain carboxyl group or side chain carboxyl group represented by Asp or Glu
- a hydroxy group on the aromatic ring phenol group represented by Tyr
- trityl chloride resin Trt resin
- CTC resin 2-chlorotrityl chloride resin
- an aliphatic hydroxy group fatty alcohol group typified by Ser or Thr
- the resin is trityl chloride resin (Trt resin), 2-chlorotrityl chloride resin (CTC resin) or It is preferable to use 4-methyltrityl chloride resin (Mtt resin).
- a resin may be described as a resin.
- the type of polymer constituting the resin is also not particularly limited. In the case of a resin composed of polystyrene, either 100-200 mesh or 200-400 mesh may be used.
- the cross-linking rate is also not particularly limited, but 1% DVB (divinylbenzene) cross-linking is preferable.
- examples of the type of polymer constituting the resin include TentaGel (registered trademark) and ChemMatrix (registered trademark).
- the substituent includes, for example, alkyl, alkoxy, fluoroalkyl, fluoroalkoxy, oxo, aminocarbonyl, alkylsulfonyl, alkyl.
- substituents include sulfonylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, halogen, nitro, amino, monoalkylamino, dialkylamino, cyano, carboxyl, alkoxycarbonyl, formyl and the like.
- substituents may be added to each of these, and these substituents are also not limited, and any substitution including, for example, a halogen atom, an oxygen atom, a sulfur atom, a nitrogen atom, a boron atom, a silicon atom, or a phosphorus atom.
- a halogen atom an oxygen atom, a sulfur atom, a nitrogen atom, a boron atom, a silicon atom, or a phosphorus atom.
- One or two or more may be freely selected independently from the group. That is, examples thereof include alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, cycloalkyl, etc., which may be substituted.
- the compounds described herein can be salts thereof or solvates thereof.
- Salts of the compounds include, for example, hydrochloride; hydrobromide; hydroiodide; phosphate; phosphonate; sulfate; methanesulfonate, p-toluenesulfonate and other sulfonates.
- Carborates such as acetate, citrate, malate, tartrate, succinate, salicylate; or alkali metal salts such as sodium and potassium salts; alkaline earth such as magnesium and calcium salts Metallic salts; include ammonium salts such as ammonium salts, alkylammonium salts, dialkylammonium salts, trialkylammonium salts, tetraalkylammonium salts and the like. These salts are produced, for example, by contacting the compound with an acid or base.
- the solvate of a compound is a phenomenon in which a solute molecule attracts a solvent molecule in a solution to form one molecular group, and if the solvent is water, it is called a hydrate.
- the compounds described herein are solvents with an organic solvent such as alcohol (eg, methanol, ethanol, 1-propanol, 2-propanol, etc.), dimethylformamide, or diglyme, or a single solvent selected from water and the like. It may be a Japanese product or a solvent product with a plurality of solvents.
- amino acid in the present specification includes natural amino acids and unnatural amino acids (sometimes referred to as amino acid derivatives). Further, in the present specification, “amino acid” may mean an amino acid residue.
- amino acid means Gly, Ala, Ser, Thr, Val, Leu, Ile, Phe, Tyr, Trp, His, Glu, Asp, Gln, Asn, Cys, Met, Lys, Arg, Pro. Point to.
- the unnatural amino acid is not particularly limited, and examples thereof include ⁇ -amino acids, D-type amino acids, N-substituted amino acids, ⁇ , ⁇ -di-substituted amino acids, amino acids having different side chains from natural amino acids, and hydroxycarboxylic acids. .. As the amino acids in the present specification, any configuration is allowed.
- the selection of the side chain of the amino acid is not particularly limited, but in addition to the hydrogen atom, for example, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, a heteroaralkyl group, a cycloalkyl group, or a spiro bond. It is freely selected from the cycloalkyl groups. Substituents may be added to each, and these substituents are not limited, and any substituent including, for example, a halogen atom, an O atom, an S atom, an N atom, a B atom, a Si atom, or a P atom.
- One or two or more may be freely selected independently from the above. That is, an alkyl group, an alkoxy group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, a cycloalkyl group, etc., which may be substituted, or an oxo, aminocarbonyl, a halogen atom, etc. Illustrated.
- the amino acid herein may be a compound having a carboxyl group and an amino group in the same molecule (even in this case, imino acids such as proline and hydroxyproline are also amino acids. included).
- halogen-derived substituent examples include fluoro (-F), chloro (-Cl), bromo (-Br), and iodine (-I).
- oxy examples include alkoxy, cycloalkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, aralkyloxy and the like.
- Examples of carbonyloxy include alkylcarbonyloxy, cycloalkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, aralkylcarbonyloxy and the like.
- Examples of carbonylthio include alkylcarbonylthio, cycloalkylcarbonylthio, alkenylcarbonylthio, alkynylcarbonylthio, arylcarbonylthio, heteroarylcarbonylthio, aralkylcarbonylthio and the like.
- Examples of carbonylamino include alkylcarbonylamino, cycloalkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, aralkylcarbonylamino and the like.
- sulfonylamino examples include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, aralkylsulfonylamino and the like.
- aminosulfonyl examples include alkylaminosulfonyl, cycloalkylaminosulfonyl, alkenylaminosulfonyl, alkynylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl and the like.
- groups in which the H atom bonded to the N atom in -SO 2- NHR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl can be mentioned.
- sulfamoylamino examples include alkylsulfamoylamino, cycloalkylsulfamoylamino, alkenyl sulfamoylamino, alkynylsulfamoylamino, arylsulfamoylamino, hetero.
- Aryl sulfamoyl amino, aralkyl sulfamoyl amino and the like can be mentioned.
- the two H atoms bonded to the N atom in -NH-SO 2- NHR are substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. It may be substituted, and these two substituents may form a ring.
- thio As an example of thio (-S-R), it is selected from among alkylthio, cycloalkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, aralkylthio and the like.
- sulfinyl examples include alkylsulfinyl, cycloalkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heteroarylsulfinyl, aralkylsulfinyl and the like.
- sulfonyls examples include alkylsulfonyls, cycloalkylsulfonyls, alkenylsulfonyls, alkynylsulfonyls, arylsulfonyls, heteroarylsulfonyls, aralkylsulfonyls and the like.
- secondary amino examples include alkylamino, cycloalkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, aralkylamino and the like.
- tertiary aminos are independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, etc., such as alkyl (aralkyl) amino.
- Amino groups having any two substituents may be mentioned, and these any two substituents may form a ring.
- the three substituents R, R', and R'' on the N atom are alkyl, cycloalkyl, alkenyl, alkynyl, aryl. , Heteroaryl, groups independently selected from aralkyl, for example, alkyl (aralkyl) (aryl) amidino and the like.
- substituted guanidinos include R, R', R', and R''' as alkyl, cycloalkyl, alkenyl, alkynyl. , Aryl, Heteroaryl, and groups independently selected from alkynes, or groups in which these groups form a ring, and the like can be mentioned.
- aminocarbonylamino examples include R, R', and R'' of hydrogen atom, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl. Examples thereof include groups independently selected from the above, or groups forming a ring.
- substituent derived from the B atom examples include boron (-BR (R')) and dioxyboryl (-B (OR) (OR')). These two substituents R and R'are independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, etc., or they may form a ring. .. Specific examples thereof include a cyclic boryl group, and more specific examples thereof include a pinacholate boryl group, a neopentane diolat boryl group, and a catecholate boryl group.
- substituent on the nitrogen atom of the N-substituted amino acid in the present specification include alkyl, C 1- C 6 alkyl, C 1 -C 4 alkyl, methyl, C 7- C 14 aralkyl, benzyl, and phenethyl. Illustrated.
- the main chain amino group of an amino acid may be unsubstituted (-NH 2 ) or substituted (ie, -NHR, where R may have a substituent, alkyl, alkenyl, alkynyl, aryl. , Heteroaryl, aralkyl, cycloalkyl, and a carbon chain bonded to an N atom such as proline and a carbon atom at the ⁇ -position may form a ring).
- Amino acids in which such a main chain amino group is substituted may be referred to as "N-substituted amino acids" in the present specification.
- N-substituted amino acid in the present specification, N-alkyl amino acid, NC 1- C 6 alkyl amino acid, NC 1 -C 4 alkyl amino acid, N-methyl amino acid, NC 7 -C 14 aralkyl amino acid, N- Examples thereof include, but are not limited to, benzyl amino acid and N-phenethyl amino acid.
- amino acid includes all isotopes corresponding to each.
- An isotope of an “amino acid” is one in which at least one atom is replaced by an atom having the same atomic number (number of protons) but a different mass number (sum of the numbers of protons and neutrons).
- isotopes included in the "amino acids" of the present specification include hydrogen atom, carbon atom, nitrogen atom, oxygen atom, phosphorus atom, sulfur atom, fluorine atom, chlorine atom, etc., respectively, 2 H, 3 Includes H, 13 C, 14 C, 15 N, 17 O, 18 O, 32 P, 35 S, 18 F, 36 Cl, etc.
- the term "about”, when used in combination with a numerical value, means a value range of + 10% and -10% of the numerical value.
- the meaning of the terms “and / or” includes any combination of “and” and “or” as appropriate. Specifically, for example, “A, B, and / or C” includes the following seven variations; (i) A, (ii) B, (iii) C, (iv) A and B, (v) A and C, (vi) B and C, (vii) A, B, and C.
- the present invention is a method for producing a peptide compound, which comprises a step of condensing a first amino acid or peptide and a second amino acid or peptide in the presence of an additive and a condensing agent to obtain a condensate.
- the peptide compound obtained by the production method of the present invention may be an intermediate or a final product of an amino acid or peptide extension step by a solid phase method or a liquid phase method.
- the extension step can be performed a plurality of times depending on the length of the amino acid sequence of the desired peptide compound, and the condensation step according to the present invention is included at least once in the extension step and may be included a plurality of times.
- a method known in the present technology can be used for the condensation step other than the condensation step according to the present invention.
- the condensate obtained by the condensation step of the present invention can be a peptide compound having a desired sequence.
- the condensate obtained by the condensation step of the present invention has a partial structure of the peptide compound. Included in it.
- the "first amino acid” may be a natural amino acid or an unnatural amino acid.
- the "first peptide" may be composed of only natural amino acids, only unnatural amino acids, or any combination of natural and unnatural amino acids.
- the first amino acid or first peptide is preferably an amino acid, more preferably an unnatural amino acid.
- the first amino acid or first peptide may be an amino acid or peptide in which the backbone amino group is not protected.
- the unprotected backbone amino group is preferably at the N-terminus of the first amino acid or first peptide.
- the first amino acid or the C-terminal amino acid of the first peptide is supported on a solid-phase synthesis resin (resin).
- a solid-phase synthesis resin resin
- the N-terminal and / or C-terminal amino acids of the first amino acid or the first peptide are unnatural amino acids, especially N-substituted amino acids such as N-alkyl amino acids, due to the premature cleavage, the conventional method.
- the desired condensation reaction may not proceed sufficiently. This is remarkable when a trityl-based atomic group is used as a resin linker that binds a resin for solid-phase synthesis to an amino acid. Even in such a case, the condensation reaction can be efficiently promoted by using the method of the present invention.
- the N-alkyl amino acid when the N-terminal and / or C-terminal amino acid of the first amino acid or the first peptide is an N-alkyl amino acid, the N-alkyl amino acid may have a side chain different from that of a natural amino acid. Examples thereof include ⁇ , ⁇ , ⁇ amino acids, and N-alkyl ⁇ amino acids are preferably exemplified.
- N-terminal amino acid of the first amino acid or the first peptide and / or the C-terminal amino acid of the first peptide include those having the following formula (1).
- R 11 is hydrogen.
- R 11 means a binding point with an adjacent amino acid, and the amino acid of the formula (1) is usually the relevant amino acid. Form an amide bond with an adjacent amino acid at the site.
- P 11 is hydrogen or C 1 -C 6 alkyl
- R 12 is hydrogen, CONR 12A R 12B , COOR 12c , C 1 -C 6 alkyl, C 3 -C 8 Cycloalkyl, C 7- C 14 aralkyl, 5-10 membered heteroaryl C 1- C 6 alkyl, protected 5-10 membered heteroaryl C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, protected C 1 -C 6 Hydroxyalkyl, C 1- C 6 Carboxyalkyl, Protected C 1 -C 6 Carboxyalkyl, C 1 -C 6 Aminoalkyl, Protected C 1 -C 6 Aminoalkyl, C 1 -C 6 Alkthio C 1 -C 6 Alkyl Is.
- R 12 is CONR 12A R 12B , then R 12A and R 12B are independently C 1- C 4 alkyl (preferably methyl, ethyl), or R 12A and R 12B are bound to them.
- a 4- to 8-membered ring preferably a piperidine ring, an azetidine ring, a pyrrolidine ring, a morpholine ring, or 3- Oxa-8-azabicyclo [3.2.1] octane ring is formed.
- R 12 is COOR 12C , then R 12C is allyl, t-butyl, or benzyl.
- R 12 is C 1- C 6 alkyl, then R 12 is preferably methyl, isopropyl, or isobutyl.
- R 12 is C 3- C 8 cycloalkyl, then R 12 is preferably cyclopentyl, or cyclohexyl.
- R 12 is C 7- C 14 aralkyl, then R 12 is preferably benzyl or phenethyl.
- R 12 is a 5- to 10-membered heteroaryl C 1- C 6 alkyl, preferably R 12 is a 5- to 10-membered heteroarylmethyl or a 5- to 10-membered heteroarylethyl. Further, when R 12 is a protected 5- to 10-membered heteroaryl C 1- C 6 alkyl, it is preferable that R 12 has a functional group contained in the above-mentioned group, for example, an amino group protected by a Boc group. ..
- R 12 is C 1- C 6 hydroxyalkyl
- R 12 is preferably hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, more preferably 1-hydroxyethyl.
- R 12 is a protected C 1 -C 6 hydroxyalkyl
- R 12 is a protecting group of the group described above is a hydroxyl group, for example, preferably those that are protected by the Bzl group and tBu group.
- R 12 is C 1- C 6 carboxyalkyl
- R 12 is preferably carboxymethyl, 1-carboxyethyl, 2-carboxyethyl, more preferably 2-carboxyethyl.
- R 12 is a protecting group of the group is a carboxyl group described above, for example, preferably those that are protected by the Bzl group and tBu group.
- R 12 is C 1- C 6 aminoalkyl
- R 12 is preferably 4-aminobutyl.
- R 12 is preferably one in which the above-mentioned group is protected by an amino protecting group, for example, a Boc group.
- R 12 is C 1- C 6 alkylthio C 1- C 6 alkyl, then R 12 is preferably 2-methylthioethyl.
- P 11 and R 12 combine with the nitrogen atom to which P 11 is attached and the carbon atom to which R 12 is attached to form a 4- to 7-membered saturated heterocycle.
- a 4- to 7-membered saturated heterocycle an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, and a morpholine ring are preferable.
- Q 12 is hydrogen, or C 1- C 6 alkyl, preferably hydrogen or methyl.
- L 11 is a single bond or -CH 2- .
- R 13 means the binding point with the resin for solid phase synthesis.
- R 13 means the binding point with the adjacent amino acid, and the amino acid of the formula (1) is usually used as the amino acid. It forms an amide bond with an adjacent amino acid at the site.
- N-terminal and / or C-terminal amino acids of the first amino acid or the first peptide for example, MeAsp-pip, MeAsp-aze, MeAsp-pyrro, MeAsp-mor, MeAsp-mor (26- bicyc), MeAsp-OtBu, MeAsp-NMe2, MeVal, MeGly, MeAla, MeLeu, D-3-MeAbu, bMeAla, MeIle, MeGly (cPent), MeChg, MePhe, MeTrp (Boc), MeThr (Bzl), MeGlu ( OtBu), MeLys (Boc), MeMet, Aze (2), Aib, etc.
- the first amino acid or peptide is solid-phased at a high carrying amount (for example, 0.5 mmol / g or more based on the Fmoc quantification method) so that the peptide may be shed from the resin by the conventional method. Even when it is supported on a synthetic resin, a condensate can be obtained while maintaining the amount of support. Therefore, in the method of the present invention, the amount of the first amino acid or peptide supported on the resin for solid phase synthesis is an arbitrary amount, for example, 0.2 mmol / g or more and 0.8 mmol / g or less based on the Fmoc quantification method. It can be used, and the reaction can be efficiently advanced even with a high loading amount of 0.3 mmol / g or more, and further 0.5 mmol / g or more.
- a high carrying amount for example, 0.5 mmol / g or more based on the Fmoc quantification method
- the "second amino acid” may be a natural amino acid or an unnatural amino acid.
- the second amino acid or peptide may be an amino acid or peptide in which the backbone carboxyl group is not protected.
- the unprotected backbone carboxyl group is preferably located at the C-terminus of the second amino acid or peptide.
- the "second peptide" may be composed of only natural amino acids, only unnatural amino acids, or any combination of natural and unnatural amino acids.
- the C-terminal amino acid of the second amino acid or second peptide is an unnatural amino acid, particularly an N-substituted amino acid such as an N-alkyl amino acid, or an amino acid having two or more carbon atoms in its side chain (eg,).
- an N-substituted amino acid such as an N-alkyl amino acid
- an amino acid having two or more carbon atoms in its side chain eg, the condensation reaction may not proceed sufficiently by the conventional method. Even in such a case, efficient condensation is possible by using the method of the present invention.
- the amino group of the second amino acid or peptide is preferably protected by a protecting group.
- a protecting group include those described above as "protecting groups for amino groups", and specific examples thereof include protecting groups having an Fmoc skeleton, Cbz, Boc, Teoc, and Alloc.
- the "protecting group having an Fmoc skeleton” means a Fmoc group or a group in which an arbitrary substituent is introduced at an arbitrary position in the constituent skeleton of the Fmoc group.
- Specific examples of the protecting group having such an Fmoc skeleton include a protecting group represented by the following formula.
- R 1 to R 8 are independently selected from the group consisting of hydrogen, C 1- C 8 alkyl, C 1 -C 8 fluoroalkyl, halogen, sulfo, and trimethylsilyl.
- R 9 to R 10 are independently hydrogen or methyl).
- a protective group having an Fmoc skeleton for example, a 9-fluorenylmethyloxycarbonyl (Fmoc) group, a 2,7-di-tert-butyl-Fmoc (Fmoc (2,7tb)) group, 1 -Methyl-Fmoc (Fmoc (1Me)) group, 2-fluoro-Fmoc (Fmoc (2F)) group, 2,7-dibromo-Fmoc (Fmoc (2,7Br)) group, 2-monoisooctyl-Fmoc ( mio-Fmoc) group, 2,7-diisooctyl-Fmoc (dio-Fmoc) group, 2,7- (3,3,4,4,5,5,6,6,7,7,8,8,8) -Tridecafluorooctyl) -Fmoc (tdf-Fmoc) group, 2,7-
- amino acid at the C-terminal of the second amino acid or the second peptide is a ⁇ -branched amino acid
- specific examples of the ⁇ -branched amino acid include those having the following formula (2A).
- formula (2A) is hydrogen or C 1 -C 6 alkyl. If P 21 is C 1- C 6 alkyl, it is preferably methyl.
- R 21 and R 22 are independently C 1- C 4 alkyl, C 1 -C 6 alkoxy, or C 1 -C 6 alkoxy C 1 -C 6 alkyl, respectively. , R 21 and R 22 together with the carbon to which they bind form a 3- to 8-membered alicyclic ring. If R 21 and R 22 are C 1- C 4 alkyl, C 1 -C 6 alkoxy, or C 1 -C 6 alkoxy C 1 -C 6 alkyl, then R 21 and R 22 are preferably methyl, ethyl, tert. -Butoxy, preferred combinations of R 21 and R 22 include methyl and methyl, methyl and ethyl, methyl and tert-butoxy.
- the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring. ..
- R 23 means the binding point of the amino group with the protecting group.
- R 23 means the binding point with the adjacent amino acid, and usually the amino acid of the formula (2A) is It forms an amide bond with an adjacent amino acid at the site.
- ⁇ -branched amino acids of such a second amino acid or the C-terminal amino acid of the second peptide MeVal, D-MeVal, Val, Ile, MeIle, MeChg, Chg, MeGly (cPent) , Gly (cPent), MeGly (cBu), Gly (cBu), MeGly (cPr), Gly (cPr), MeThr (tBu), Thr (tBu) and the like.
- the amino acid at the C-terminal of the second amino acid or the second peptide is an ⁇ , ⁇ -di-substituted amino acid
- the ⁇ , ⁇ -di-substituted amino acid specifically has the following formula (2B). Can be mentioned.
- P 22 is hydrogen or C 1 -C 6 alkyl, preferably hydrogen when P 22 is C 1 -C 6 alkyl.
- R 23 and R 24 are selected independently of C 1- C 6 alkyl, C 2 -C 6 alkenyl, or optionally substituted C 7 -C 14 aralkyl, or R 23 and R 24 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle. If R 23 and R 24 are C 1- C 6 alkyl, preferably methyl, ethyl, or isopropyl, and if R 23 and R 24 are C 2- C 6 alkenyl, they are preferably allyl, R.
- R 23 and R 24 are C 7- C 14 aralkyls, they are preferably benzyls that may be substituted with halogen.
- the combination of R 23 and R 24 is preferably benzyl, which may be substituted with methyl and methyl, methyl and ethyl, methyl and isopropyl, methyl and isobutyl, methyl and allyl, and methyl and halogen.
- R 23 and R 24 form a 3- to 8-membered alicyclic ring together with the carbon atom to which they are bonded, the cyclopropane ring, cyclobutane ring, and cyclo are preferable as the alicyclic ring.
- R 25 means the bonding point with the protecting group of the amino group.
- R 25 means the binding point with the adjacent amino acid, and usually the amino acid of the formula (2B) is It forms an amide bond with an adjacent amino acid at the site.
- Aib (Me) Abu, (Me) Leu, (Me) Algly, as ⁇ , ⁇ -di-substituted amino acids of the C-terminal amino acid of the second amino acid or the second peptide.
- Examples thereof include (Me) Phe, (Me) Phe (3-I), 1-ACPrC, cVal, cLeu, cHex, and Athpc.
- the second amino acid, or the C-terminal amino acid of the second peptide is an N-alkyl amino acid, specifically MeAsp-pip, MeAsp-aze, MeAsp-pyrro, MeAsp-mor, MeAsp.
- MeAsp-OtBu D-3-MeAbu
- bMeAla MeGly, MeAla, MeLeu, MePhe
- Pro MeAsp-NMe2
- MeVal, MeIle MeChg, MeGly (cPent), MeGly (cBu), MeGly (cPr), MeThr (tBu), D-MeVal, MeTrp (Boc), MeThr (Bzl), MeGlu (OtBu), MeLys (Boc), MeMet, etc., preferably MeVal or MeIle can be mentioned.
- the second amino acid, or the C-terminal amino acid of the second peptide has two or more carbon atoms in its side chain and corresponds to a ⁇ -branched amino acid or an ⁇ , ⁇ -di-substituted amino acid.
- Lys (Z), Glu (OBzl), or Ser (tBu) corresponds to an amino acid having two or more carbon atoms in the side chain.
- the second amino acid or peptide is used in an equal amount or an excess amount with respect to the first amino acid or peptide.
- the molar ratio of the second amino acid or peptide to the first amino acid or peptide is the lower limit selected from the group consisting of 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0 and 9.0.
- the molar ratio of the second amino acid or peptide to the first amino acid or peptide is preferably 1.5 or more, more preferably 2 or more.
- the molar ratio of the second amino acid or peptide to the first amino acid or peptide is preferably 8 or less, more preferably 4 or less.
- the molar ratio of the second amino acid or peptide to the first amino acid or peptide is most preferably about 2.
- Examples of the additive used for the condensation reaction of the present invention include Oxyma, HOBt, HOOBt, HOAt and the like.
- the additive is used in a number of moles smaller than the number of moles of the second amino acid or peptide.
- the molar ratio of the additive to the second amino acid or peptide is less than 1.
- the molar ratio is preferably 0.8 or less, for example 0.1 to 0.8.
- the molar ratio of the additive to the second amino acid or peptide is the lower limit selected from the group consisting of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6 and 0.7, and 0.2, It can be a range that can be specified by a combination with an upper limit selected from the group consisting of 0.3, 0.4, 0.5, 0.6, 0.7 and 0.8.
- the molar ratio of the additive to the second amino acid or peptide is more preferably 0.3-0.7.
- the molar ratio of the additive to the second amino acid or peptide is preferably 0.7 or less. .. Specifically, when the molar ratio of the second amino acid or peptide to the first amino acid or peptide is 1 to 2, the molar ratio of the additive to the second amino acid or peptide is in the range of 0.7 or less and in the range of 0.6 or less. , 0.5 or less range, 0.4 or less range, 0.3 or less range, 0.2 or less range or 0.1 or less range.
- the molar ratio of the second amino acid or peptide to the first amino acid or peptide is 1-2
- the molar ratio of the additive to the second amino acid or peptide is 0.1, 0.2, 0.3, 0.4.
- a range that can be specified by a combination of a lower limit selected from the group consisting of, 0.5, and 0.6, and an upper limit selected from the group consisting of 0.2, 0.3, 0.4, 0.5, 0.6, and 0.7. can.
- the second amino acid or peptide if the molar ratio of the second amino acid or peptide to the first amino acid or peptide (this molar ratio is sometimes referred to as the "first molar ratio") is 2 or greater, the second amino acid.
- the molar ratio of the additive to the peptide is preferably "(first molar ratio) -1" or less. Specifically, when the molar ratio of the second amino acid or peptide to the first amino acid or peptide is 2 or more, the molar ratio of the additive to the second amino acid or peptide is (1st to the first amino acid or peptide).
- the molar ratio of the second amino acid or peptide to the first amino acid or peptide is 2 or more
- the molar ratio of the additive to the second amino acid or peptide is (to the first amino acid or peptide).
- the molar ratio of the additive to the first amino acid or peptide can be 0.5-2.0.
- the molar ratio of the additive to the first amino acid or peptide is from 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, and 1.9.
- It can be used in a molar ratio in the range that can be specified by.
- the molar ratio of the additive to the first amino acid or peptide is particularly preferably about 1.
- Examples of the condensing agent used in the condensation reaction of the present invention include DIC, DCC, EDCI, EDCI / HCl and the like.
- the condensing agent is used in an amount equal to or greater than the number of moles of the second amino acid or peptide.
- the molar ratio of the condensing agent to the second amino acid or peptide can be in the range of 1 or more, 2 or more, 3 or more, or 4 or more.
- the molar ratio of the condensing agent to the second amino acid or peptide is 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4,
- the lower limit selected from the group consisting of 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9 and 4.0, and 1.1, 1.2, 1.3, 1.4, 1.5.
- 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0 , 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, and 5.0 can be the range that can be specified by the combination with the upper limit selected from the group.
- Preferred ranges for the molar ratio of the condensing agent to the second amino acid or peptide include 1.0 to 5.0, 1.2 to 4.0, 1.2 to 4.0, 1.2 to 3.0 and 2.0 to 3.0.
- the condensing agent is used in equal or excess amounts with respect to the first amino acid or peptide.
- the molar ratio of the condensing agent to the first amino acid or peptide is in the range of 1.0 or more, 1.1 or more, 1.2 or more, 1.3 or more, 1.4 or more, 1.5 or more, 1.6 or more range, 1.7 or more range, 1.8 or more range, 1.9 or more range, 2.0 or more range, 2.1 or more range, 2.2 or more range, 2.3 or more range, 2.4 or more range, 2.5 or more range, 2.6 or higher range, 2.7 or higher range, 2.8 or higher range, 2.9 or higher range, 3.0 or higher range, 3.1 or higher range, 3.2 or higher range, 3.3 or higher range, 3.4 or higher range, 3.5 or higher range, 3.6 or higher range, 3.7 or higher range, 3.8 or higher range, 3.9 or higher range, 4.0 or higher range, 4.1 or higher range, 4.2 or higher range, 4.3 or higher
- the molar ratio of the condensing agent to the first amino acid or peptide is 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, Lower limit selected from the group consisting of 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5
- the molar ratio of the condensing agent to the first amino acid or peptide is preferably 1.3 or more, more preferably 2.0 or more.
- the molar ratio of the condensing agent to the first amino acid or peptide is preferably 10 or less, more preferably 8.0 or less.
- the molar ratio of the condensing agent to the first amino acid or peptide is most preferably about 4.
- the molar ratio of condensing agent and additive to the second amino acid or peptide is The molar ratio of the condensing agent to the second amino acid or peptide is the lower limit selected from the values 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, and 2.0, as well as 2.0, 2.1, It can be a range that can be specified by a combination with an upper limit selected from values consisting of 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, and 3.0.
- the lower limit of the molar ratio of the additive to the second amino acid or peptide selected from values consisting of 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, and 0.5.
- the molar ratio of the second amino acid or peptide, condensing agent, and additive to the first amino acid or peptide is.
- the molar ratio of the second amino acid or peptide to the first amino acid or peptide is 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, A lower limit selected from values consisting of 2.7, 2.8, 2.9 and 3.0, as well as 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7.
- the molar ratio of the condensing agent to the first amino acid or peptide is the lower limit selected from the values 1.0, 2.0, 3.0 and 4.0 and the upper limit selected from the values 5.0, 6.0, 7.0, 8.0 and 9.0. It can be a range that can be specified by the combination,
- the molar ratio of the additive to the first amino acid or peptide is the lower limit selected from values consisting of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1.0, as well as 1.1, 1.2, 1.3, 1.4.
- the condensation reaction of the present invention can be carried out at a reaction temperature of 0 to 100 ° C, preferably 5 to 60 ° C, more preferably 10 to 40 ° C.
- the condensation reaction of the present invention can be carried out in a reaction time of 10 minutes to 1 week, preferably 10 minutes to 3 days, more preferably 1 hour to 2 days.
- the additive is Oxyma and the condensing agent is DIC, DCC, EDCI, or EDCI / HCl.
- the additive is Oxyma and the condensing agent is DIC.
- the condensation reaction of the present invention can be carried out in a suitable solvent.
- an aprotic solvent can be used, and examples thereof include an amide solvent, an ester solvent, an ether solvent, an alkylnitrile solvent, and a urea solvent.
- Amide solvents include DMF, DMA, and NMP.
- Examples of the ester solvent include ethyl acetate and dimethyl carbonate.
- Examples of the ether solvent include tetrahydrofuran, 2-methyltetrahydrofuran and the like.
- the alkylnitrile-based solvent include acetonitrile.
- the urea solvent include DMI and TMU.
- the method of the present invention can be applied to both the solid phase method and the liquid phase method.
- the method of the present invention can be carried out by contacting the first amino acid or peptide bound to the resin with the second amino acid or peptide, the condensing agent, and the additive.
- the order in which the second amino acid or peptide, the condensing agent, and the additive are brought into contact with the first amino acid or peptide is arbitrary, and the second amino acid or peptide, the condensing agent, with respect to the first amino acid or peptide.
- the additives may be brought into contact at the same time or in sequence.
- the first amino acid or peptide may be contacted with a premixed mixture of all or any of the second amino acid or peptide, condensing agent, and additive.
- a mixture thereof with a suitable solvent may be used.
- the method of the present invention may be carried out using a solid phase synthesizer.
- the method of the invention can be carried out by mixing a first amino acid or peptide bound to a resin with a second amino acid or peptide, a condensing agent and an additive in a suitable solvent.
- a pretreatment the solid-phase synthesis resin is swollen by contact with an appropriate solvent to efficiently proceed with the desired condensation reaction. Can be done.
- the amount of the solvent used in this pretreatment can be any amount as long as the swollen resin is immersed in the solvent. For example, when DMF is used as the solvent, 3v / w to 15v / w.
- the solvent amount is described as 4v / w, it means that the solvent amount is 4 ml with respect to 1 g of the resin weight.
- the reaction solution is discharged from the solid-phase synthesizer, and the remaining solid-phase synthesis resin is washed with an appropriate solvent to discharge excess reagents and by-products, and the solid-phase synthesis resin is discharged.
- the target peptide compound bound to can be obtained.
- the solvent suitable for washing and / or swelling the solid-phase synthesis resin include amide-based and solvent alcohol-based solvents, and DMF or 2-propanol is preferable. These solvents may be used multiple times or may be used alternately.
- the swollen solid-phase synthetic resin can be shrunk as needed, for which washing with an alcohol-based solvent or an ether-based solvent is used. Methanol is preferable as the alcohol solvent, and MTBE is preferable as the ether solvent.
- any resin can be used because the yield of the condensation reaction and the purity of the condensate can be improved as compared with the conventional method even when the premature cleavage does not occur at the same time.
- resin linkers in which premature cleavage can occur include those classified as acid-sensitive "H ( ⁇ 5% TFA in CH 2 Cl 2 )" described in the Novabiochem solid phase synthesis handbook, and resins having such resin linkers are exemplified.
- resin linkers such as 2-chlorotrityl chloride resin (CTC resin), TGT resin, trityl chloride resin (Trt resin), 4-methyltrityl chloride resin (Mtt resin), 4-methoxytrityl chloride resin (Mmt resin).
- resin linkers for solid phase synthesis in which trityl-based atomic groups are used such resins are sometimes referred to as "trityl-based resins"
- the present invention is particularly useful when such resins are used. ..
- the type of polymer constituting the resin is not particularly limited, but a resin composed of polystyrene is preferable. Further, a solid-phase synthesis resin having a particle size of about 100-200 mesh or 200-400 mesh can be preferably used.
- the cross-linking rate of the resin is not particularly limited, but 1% DVB (divinylbenzene) cross-linking is preferable.
- Examples of the type of polymer constituting the resin include TentaGel (registered trademark) and ChemMatrix (registered trademark).
- a mixture of a second amino acid or peptide, a condensing agent, and an additive premixed in a solvent may be previously prepared and used in the condensation reaction.
- the mixing time is not particularly limited, but is preferably 0 minutes to 2 hours, more preferably 0 minutes to 1 hour, and even more preferably 30 minutes.
- Stirring or shaking the resin using an automatic synthesizer can be important in allowing the resin to fully permeate the reaction solution and allow the reaction to proceed as desired.
- the stirring speed, shaking speed, and frequency thereof are not particularly limited, but excessive stirring may cause physical damage to the resin. Therefore, for example, stirring at 60 rpm may be performed every hour for about 2 minutes. Further, if the penetration is sufficient, it is not always necessary to stir or shake.
- the method of the present invention may further include a step of removing the resin for solid phase synthesis, for which a method known in the art can be used.
- the peptide compound extended to the desired sequence can be desorbed from the resin and isolated.
- the method of the invention may further include a step of removing the protecting group, for which methods known in the art can be used.
- the methods described in "Greene's,” Protective Groups in Organic Synthesis “(5th edition, John Wiley & Sons 2014)" can be mentioned, and these may be appropriately used according to the reaction conditions.
- the amino group of the second amino acid or the amino group of the N-terminal amino acid of the second peptide is protected by a protective group
- the following condensation is carried out by removing the protective group. You can prepare for the reaction.
- the protecting group may be removed at the same time as the condensation reaction or may be removed separately from the condensation reaction.
- the invention uses the methods of the invention to obtain linear peptide compounds, followed by Comprehensive Organic Transformations, A Guide to Functional Group Preparations, 3rd Edition (R.C. Larock), or March's Advanced Organic. Cycling the N-terminal side group and the C-terminal side group by a known method described in Chemistry: Reactions, Mechanisms, and Structure, 7th Edition (M.B. Smith, J. March), etc.
- the present invention also relates to a method for producing a cyclic peptide compound.
- the present invention also relates to a method for suppressing premature cleavage using the method of the present invention.
- 1-Ethyl-3- (3-dimethylaminopropyl) carbodiimide was added dropwise at 12.2 mL (69.5 mmol, 1.1 eq) at 0 ° C. over 10 minutes using a dropping funnel. After the dropping, the dropping funnel was washed twice with 1.25 mL of N, N-dimethylformamide. Five hours after the start of the reaction, 269 mL of 2-MeTHF was added, and then 135 mL of a 0.5 mol / L hydrochloric acid aqueous solution was added over 10 minutes. After draining the aqueous layer, 135 mL of a 5% aqueous sodium carbonate solution was added to the organic layer.
- the flask was immersed in an ice bath and TMSOTf was added with a 0.79 mL (4.4 mmol, 1.4 eq) syringe when the internal temperature reached 1 ° C.
- the temperature was raised to room temperature 5 minutes after the completion of the dropping, and 1 hour later, it was confirmed by HPLC (method Aa) that the reaction rate was 100%.
- the reaction vessel was immersed in an ice bath again, and when the internal temperature reached 5 ° C., 15 mL of a 5% aqueous sodium carbonate solution was added. After adding the aqueous sodium carbonate solution, the reaction solution was stirred for several minutes, and then the stirring was stopped.
- the reaction vessel was transferred to a 50 mL separatory funnel, separated into layers, and then the aqueous layer was separated. The resulting aqueous layer was washed with 15 mL of MTBE. After adding 15 mL of MTBE to the separated aqueous layer, 1.1 mL of phosphoric acid (mass fraction of 85% or more) was added. After shaking the solution with a separating funnel, the solution was separated and the organic layer was separated. After adding magnesium sulfate to the obtained organic layer, magnesium sulfate was filtered. 1.5 mL of heptane was added to the filtrate, and the mixture was concentrated under reduced pressure to obtain 1.42 g (compound 3) of a white solid (content not measured).
- Cl-Trt (2-Cl) resin (1.25 to 1.60 mmol / g, 100-200 mesh, 1% DVB) was purchased from Watanabe Chemical Industry Co., Ltd. or SUNRESIN.
- the polymer or resin moiety when the solid phase support and the compound are bonded, the polymer or resin moiety may be indicated by ⁇ .
- the chemical structure of the linker which is the reaction site, may be indicated by connecting to ⁇ .
- the 2-chlorotrityl group of the solid phase support forms an ester bond with the side chain carboxy group of MeAsp.
- pip means a piperidino group, and in the above structure, the C-terminal carboxy group forms an amide bond with piperidine.
- the amount of solvent at the time of performing a solid-phase reaction may be expressed as a double amount (v / w).
- the standard for double the amount is the mass of Cl-Trt (2-Cl) resin in the loading step.
- 40 mL of dichloromethane is added to 3.97 g of Cl-Trt (2-Cl) resin.
- 40 / 3.97 ⁇ 10 v / w is the resin intermediate obtained in the loading step.
- the reaction solution after the de-resin reaction using the dry resin obtained after elongation is measured by LC to confirm the purity of the compound carried on the resin for solid-phase synthesis. did.
- the specific procedure is shown. Approximately 20 mg of the stretched dry resin was placed in a 5 mL disposable syringe with a filter, dichloromethane was aspirated with a 1 mL disposable syringe, and the mixture was allowed to stand at room temperature for 15 minutes. Dichloromethane was discharged, 0.20 mL of dichloromethane containing 1% TFA was added, and the mixture was shaken at room temperature for 30 seconds. The solution was drained into a 1 mL vial. An LC sample solution was prepared by diluting 40 ⁇ L of the effluent with 960 ⁇ L of acetonitrile.
- the Fmoc quantitative value (mmol / g) and the dry resin weight (g) are used.
- the amount of substance (mmol) of the target substance was calculated from the product of LC purity (area%), and the yield of the solid phase condensation reaction was evaluated.
- the specific procedure of Fmoc quantification is shown. About 20 mg of the dry resin was weighed in a 100 mL volumetric flask, and then an N, N-dimethylformamide solution containing 20% piperidine was added to make a volumetric flask. The solution was shaken for 45 minutes at room temperature.
- Fmoc quantification method (Example 2-2 to Example 2-11) About 10 mg of commercially available Fmoc-Gly-OH was weighed in a 10 mL volumetric flask, and then DMF (4 ml) was added. After shaking at room temperature for 30 minutes, DBU (40 ⁇ L) was added and the solution was shaken at room temperature for 15 minutes. Then, DMF was added and the volume was increased to 10 mL. A sample solution was prepared from 30 ⁇ L of the solution supernatant and 4 ml of DMF solution, and LC data was obtained (5 ⁇ L injection). Calibration curves were created at each wavelength of 294 nm and 304 nm from the acquired data.
- Example 1 Example 2-1 and Examples 2-12 to 2-31, Fmoc amino acids, DIC, and Oxyma were added to the amino acids of the solid-phase synthesis resin in an amount of 2 equivalents and 4 equivalents, respectively. Amino acids were extended by using 1 equivalent (Example Condition A).
- the target product (Compound 7) could be obtained in high yield.
- the production of the overextended form (Compound 8) and the epimer form (Compound 6) was 2.3 A% and 0.4 A%, respectively.
- N-dimethylformamide After draining N, N-dimethylformamide, 1.1 mL (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, 1.1 mL (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added again, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, it was washed 8 times with 1.3 mL (10 v / w) of N, N-dimethylformamide.
- the target product (Compound 10) could be obtained in high yield.
- the production of the overextended form (Compound 11) and the epimer form (Compound 7) was 1.9 A% and 0.1 A%, respectively.
- the resin (100 mg) carrying the Fmoc amino acid or peptide prepared in Solid-Phase Raw Material Synthesis 1 to 4 was placed in a solid-phase reaction vessel equipped with a filter (frit) and set in a peptide synthesizer.
- the resin was swollen by adding DCM (1.2 mL) and allowing it to stand for 30 minutes, and then the solution was drained from the frit.
- Solution 1 and solution 2 were set in the peptide synthesizer, and automatic synthesis by the peptide synthesizer was started.
- a DMF solution of DBU (2% v / v, 0.7 mL) was added to a solid-phase reaction vessel containing resin, and the Fmoc group was removed at room temperature. The reaction was carried out for 4.5 minutes for the deprotection of the first residue, and the reaction was carried out for 10 minutes for the deprotection of the second and subsequent residues, and then the solution was discharged from the frit. DMF (0.7 mL) was added thereto, and after allowing to stand for 5 minutes, the solution was discharged from the frit. This resin cleaning process was repeated three more times.
- solution 1 (0.3 mL) and solution 2 (0.36 mL) were mixed with the mixing vial of the synthesizer (Fmoc amino acid: condensing agent: additive mixing ratio of about 1.6: 2: 1) and then converted into a resin.
- the solution was added, the solid phase reaction vessel was heated to 40 ° C. or 50 ° C., and the reaction was carried out for 2.5 hours or 10 hours to carry out a condensation reaction between the amino group on the resin and the Fmoc amino acid, and then the solution was discharged from the frit.
- the resin was then washed 3 times with DMF (0.7 mL). Following this Fmoc group removal reaction, the Fmoc amino acid condensation reaction was set as one cycle, and this cycle was repeated to extend the peptide.
- the obtained resin was washed 4 times with DMF (0.7 mL), then washed 4 times with DCM (0.7 mL), and air-dried at room temperature for 48 hours.
- a part of the obtained resin (about 10 mg) was placed in a reaction vessel, and the carrying ratio of the peptide on the resin was calculated according to the above Fmoc quantification method.
- a part of the obtained resin (about 20 mg) is placed in a reaction vessel, and a TFE / DCM solution (1/1, 1 mL) containing or not containing 0.75% (v / v) DIPEA is added.
- the peptide was cut out by shaking at room temperature for 2 hours. After the reaction, the cutout solution was analyzed by LCMS.
- the theoretical Fmoc quantification value (mmol / g) after the extension reaction is calculated as follows.
- Theoretical Fmoc quantified value after elongation reaction (mmol / g) Fmoc quantified value of raw material resin (mmol / g) ⁇ Weight of raw material resin (g) ⁇ Weight of resin when 100% of target product is produced (g) ) (Equation 2)
- the weight (g) of the amino acid or peptide component on the raw material resin is calculated as follows.
- Weight of amino acid or peptide component on raw material resin (g) Quantitative value of Fmoc of raw material resin (mmol / g) x Weight of raw material resin (g) x Molecular weight of amino acid or peptide component on raw material resin (g / g / mol) x 0.001 (mol / mmol) (Equation 4)
- the recovery rate is calculated by the following equation.
- Recovery rate Actual Fmoc quantified value after extension reaction (mmol / g) ⁇ (1 ⁇ Fmoc quantified value of raw material resin (mmol / g) --Molecular weight of amino acid or peptide component on raw material resin (g / mol) ⁇ 0.001 (mol / mmol) + molecular weight (g / mol) of the peptide component of the target substance ⁇ 0.001 (mol / mmol))
- Synthesis of compound 27 under condition 1 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeVal-OH (HOAt, 40 ° C., 2.5 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 27.
- Synthetic method using amino acid-bearing resin Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeVal-OH (HOAt, 40
- Synthesis of compound 27 under condition 2 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeVal-OH (Oxyma, 50 ° C., 10 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 27.
- Synthesis of compound 28 under condition 1 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeIle-OH (HOAt, 40 ° C., 2.5 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 28.
- Synthetic method using amino acid-bearing resin Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeIle-OH (HOAt
- Synthesis of compound 28 under condition 2 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeIle-OH (Oxyma, 50 ° C., 10 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 28.
- Synthetic method using amino acid-bearing resin Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeIle-OH (O
- Synthesis of compound 29 under condition 1 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeGly (cPent) -OH (HOAt, 40 ° C., 2.5 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 29.
- synthesis method 1 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc
- Synthesis of compound 29 under condition 2 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, Fmoc-MeGly (cPent) -OH was extended (Oxyma, 50 ° C., 10 hours), and then Fmoc-Ile-OH was extended (HOAt, 40 ° C., 2.5 hours) to synthesize compound 29.
- Synthesis of compound 30 under condition 1 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeChg-OH (HOAt, 40 ° C., 2.5 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 30.
- Synthetic method using amino acid-bearing resin Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeChg-OH (HOAt
- Synthesis of compound 30 under condition 2 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeChg-OH (Oxyma, 50 ° C., 10 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 30.
- Synthesis of compound 31 under condition 1 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeLeu-OH (HOAt, 40 ° C., 2.5 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 31.
- Synthetic method using amino acid-bearing resin Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeLeu-OH (HOAt
- Synthesis of compound 31 under condition 2 Synthetic method using amino acid-bearing resin (Compound 4) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -pip) (100 mg, 0.455 mmol / g) prepared in Solid-Phase Raw Material Synthesis 1 as a starting material. According to 1, extension of Fmoc-MeLeu-OH (Oxyma, 50 ° C., 10 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 31.
- Synthesis of compound 32 under condition 1 Synthetic method using amino acid-supported resin (Compound 22) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -NMe2) (100 mg, 0.442 mmol / g) prepared in Solid-Phase Raw Material Synthesis 2 as a starting material. According to 1, extension of Fmoc-MeGly (cPent) -OH (HOAt, 40 ° C., 2.5 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 32.
- synthesis method 1 Synthetic method using amino acid-supported resin (Compound 22) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -NMe2) (100 mg, 0.442 mmol / g) prepared in Solid-Phase Raw Material Synthesis 2 as a starting material. According to 1, extension of Fmoc-MeGly (
- Synthesis of compound 32 under condition 2 Synthetic method using amino acid-bearing resin (Compound 22) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -NMe2) (100 mg, 0.442 mmol / g) prepared in Solid-Phase Raw Material Synthesis 2 as a starting material. According to 1, Fmoc-MeGly (cPent) -OH was extended (Oxyma, 50 ° C., 10 hours), and then Fmoc-Ile-OH was extended (HOAt, 40 ° C., 2.5 hours) to synthesize compound 32.
- synthesis method 1 Synthetic method using amino acid-bearing resin (Compound 22) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -NMe2) (100 mg, 0.442 mmol / g) prepared in Solid-Phase Raw Material Synthesis 2 as a starting material. According to 1, Fmoc-MeGly
- Synthesis of compound 33 under condition 1 Synthetic method using amino acid-supported resin (Compound 22) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -NMe2) (100 mg, 0.442 mmol / g) prepared in Solid-Phase Raw Material Synthesis 2 as a starting material. According to 1, extension of Fmoc-MeLeu-OH (HOAt, 40 ° C., 2.5 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 33.
- synthesis method 1 Synthetic method using amino acid-supported resin (Compound 22) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -NMe2) (100 mg, 0.442 mmol / g) prepared in Solid-Phase Raw Material Synthesis 2 as a starting material. According to 1, extension of Fmoc-MeLeu-OH (HOAt,
- Synthesis of compound 33 under condition 2 Synthetic method using amino acid-bearing resin (Compound 22) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -NMe2) (100 mg, 0.442 mmol / g) prepared in Solid-Phase Raw Material Synthesis 2 as a starting material. According to 1, extension of Fmoc-MeLeu-OH (Oxyma, 50 ° C., 10 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 33.
- synthesis method 1 Synthetic method using amino acid-bearing resin (Compound 22) (Fmoc-MeAsp (O-Trt (2-Cl) resin) -NMe2) (100 mg, 0.442 mmol / g) prepared in Solid-Phase Raw Material Synthesis 2 as a starting material. According to 1, extension of Fmoc-MeLeu-
- Synthesis of compound 34 under condition 1 Synthesis using amino acid-supported resin (Compound 24) (Fmoc-D-3-MeAbu-O-Trt (2-Cl) resin) (100 mg, 0.369 mmol / g) prepared in Solid-Phase Raw Material Synthesis 3 as a starting material. According to Method 1, extension of Fmoc-MeVal-OH (HOAt, 40 ° C., 2.5 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 34.
- synthesis method 1 Synthesis using amino acid-supported resin (Compound 24) (Fmoc-D-3-MeAbu-O-Trt (2-Cl) resin) (100 mg, 0.369 mmol / g) prepared in Solid-Phase Raw Material Synthesis 3 as a starting material. According to Method 1, extension of Fmoc-MeVal-OH (HOAt, 40 ° C., 2.5 hours
- Synthesis of compound 34 under condition 2 Synthesis of compound 34 under condition 2 (synthesis method 1) Synthesis using amino acid-bearing resin (Compound 24) (Fmoc-D-3-MeAbu-O-Trt (2-Cl) resin) (100 mg, 0.369 mmol / g) prepared in Solid-Phase Raw Material Synthesis 3 as a starting material. According to Method 1, extension of Fmoc-MeVal-OH (Oxyma, 50 ° C., 10 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 34.
- synthesis method 1 Synthesis using amino acid-bearing resin (Compound 24) (Fmoc-D-3-MeAbu-O-Trt (2-Cl) resin) (100 mg, 0.369 mmol / g) prepared in Solid-Phase Raw Material Synthesis 3 as a starting material. According to Method 1, extension of Fmoc-
- Synthesis of compound 35 under condition 1 Synthesis using amino acid-supported resin (Compound 24) (Fmoc-D-3-MeAbu-O-Trt (2-Cl) resin) (100 mg, 0.369 mmol / g) prepared in Solid-Phase Raw Material Synthesis 3 as a starting material.
- Method 1 extension of Fmoc-MeChg-OH (HOAt, 40 ° C., 2.5 hours) and then extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) were carried out to synthesize compound 35.
- Synthesis of compound 35 under condition 2 Synthesis using amino acid-bearing resin (Compound 24) (Fmoc-D-3-MeAbu-O-Trt (2-Cl) resin) (100 mg, 0.369 mmol / g) prepared in Solid-Phase Raw Material Synthesis 3 as a starting material.
- Compound 35 was synthesized by stretching Fmoc-MeChg-OH (Oxyma, 50 ° C., 10 hours) and then stretching Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) according to Method 1.
- Synthesis of compound 36 under condition 1 (synthesis method 1) Using the amino acid-supported resin (Compound 26) (Fmoc-MeGly-O-Trt (2-Cl) resin) (100 mg, 0.573 mmol / g) prepared in Solid-Phase Raw Material Synthesis 4 as a starting material, according to Synthesis Method 1, The extension of Fmoc-MeVal-OH (HOAt, 40 ° C., 2.5 hours) was followed by the extension of Fmoc-Ile-OH (HOAt, 40 ° C., 2.5 hours) to synthesize compound 36.
- synthesis method 1 Using the amino acid-supported resin (Compound 26) (Fmoc-MeGly-O-Trt (2-Cl) resin) (100 mg, 0.573 mmol / g) prepared in Solid-Phase Raw Material Synthesis 4 as a starting material, according to Synthesis Method 1, The extension of Fmoc-MeVal-OH (HOAt, 40 ° C.
- Synthesis of compound 36 under condition 2 Synthesis method 1 using amino acid-bearing resin (Compound 26) (Fmoc-MeGly- (O-Trt (2-Cl) resin)) (100 mg, 0.573 mmol / g) prepared in Solid-Phase Raw Material Synthesis 4 as a starting material.
- Fmoc-MeVal-OH was extended (Oxyma, 50 ° C., 10 hours), and then Fmoc-Ile-OH was extended (HOAt, 40 ° C., 2.5 hours) to synthesize compound 36.
- N-dimethylformamide After draining N, N-dimethylformamide, 1.3 mL (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, 1.3 ml (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added again, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, the reaction solution was washed 8 times with 1.6 mL (10 v / w) of N, N-dimethylformamide.
- Glycine capping was carried out to confirm the residual ratio of starting materials. That is, about 10 mg of the dried resin subjected to the condensation reaction was weighed in a 5 mL disposable syringe equipped with a filter, 1 mL of N, N-dimethylformamide was added, and the mixture was allowed to stand at room temperature for 15 minutes. After discharging N, N-dimethylformamide, weigh the reaction cocktail (Fmoc-Gly-OH about 70 mg and HATU about 0.11 g in a vial, suspend in 0.45 mL of N, N-dimethylformamide, and then N, 45 ⁇ L of N-diisopropylethylamine was added and shaken for 1 minute.
- reaction cocktail Fmoc-Gly-OH about 70 mg and HATU about 0.11 g in a vial
- N-dimethylformamide After draining N, N-dimethylformamide, 1.3 mL (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, 1.3 mL (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added again, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, the reaction solution was washed 8 times with 1.6 mL (10 v / w) of N, N-dimethylformamide.
- Example Condition A Using the same method as in Example Condition A, it was confirmed that the starting material residual rate was 0% in Reference Example Condition A as well.
- reaction time was shortened from 18 hours to 1 hour.
- Example condition A suppressed premium cleavage as compared with Reference Example condition A, and gave a 2-residue peptide in a good yield.
- the inhibitory effect in the case of N-Me ⁇ amino acid was remarkable.
- Example 2-31 Search experiment of reagent equivalent range that produces inhibitory effect of premature cleavage Based on the above [1 residue + 1 residue condensation experiment] (Example condition A), the result of performing the same reaction by changing the reagent equivalent is as follows. Shown in.
- Example 2-1 to 2-31 an amino acid or peptide having an N-terminal at the N-terminal under the condition that 1 equivalent or more of DIC is used with respect to the Fmoc amino acid and 1 equivalent or less of the additive is used.
- the recovery rate when extending to the third residue was over 53%, and the highest was over 90%.
- the yield and purity of Example Condition A were equal to or higher than those.
- N-dimethylformamide After draining N, N-dimethylformamide, 1.1 mL (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, 1.1 mL (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added again, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, it was washed 8 times with 1.3 mL (10 v / w) of N, N-dimethylformamide.
- Glycine capping was carried out to confirm the residual ratio of starting materials. That is, about 10 mg of the resin obtained by filtering the reaction solution after the condensation reaction was transferred as an N, N-dimethylformamide suspension to a 5 mL disposable syringe equipped with a filter. After discharging N, N-dimethylformamide, the cells were washed 3 times with 1 mL of N, N-dimethylformamide.
- Reaction cocktail (Weigh about 70 mg of Fmoc-Gly-OH and about 0.11 g of HATU in a vial, suspend in 0.45 mL of N, N-dimethylformamide, and then add 45 ⁇ L of N, N-diisopropylethylamine 1 The pale yellow uniform solution shaken for 1 minute) was aspirated with a disposable syringe and shaken at room temperature for 1 hour. After draining the reaction solution, the reaction was washed 6 times with 1 mL of N, N-dimethylformamide and then 4 times with 1 mL of dichloromethane, and then the resin removal reaction was carried out.
- Residual starting material from the sum of LC A% of Gly-cap compound (Compound 13), epimer compound (Compound 6), target substance (Compound 7), over-extended compound (Compound 8), and over-extended compound (Compound 9).
- the rate was calculated as 1.3% (1.3 ⁇ (1.3 + 79.9 + 13.4 + 2.3)).
- N-dimethylformamide After draining N, N-dimethylformamide, 1.1 mL (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, 1.1 mL (8 v / w) of N, N-dimethylformamide solution containing 20% piperidine was added again, and the mixture was shaken at room temperature for 15 minutes. After draining the reaction solution, it was washed 8 times with 1.3 mL (10 v / w) of N, N-dimethylformamide.
- the amount of solvent at the time of solid-phase reaction may be expressed as a double amount (v / w).
- the standard of double the amount in this reference example is the mass of the dry resin (Compound 14), and 0.80 mL of N, N-dimethylformamide is used for 100 mg of the dry resin.
- This solution was transferred to the reaction solution of Fmoc-c Leu-OH and shaken at room temperature for 2 hours.
- the reaction solution was transferred to a disposable syringe equipped with a filter, and the reaction solution and the resin were separated by filtration. After washing the resin twice alternately with N, N-dimethylformamide 0.80 mL (8 v / w) and isopropanol 0.80 mL (8 v / w), N, N-dimethylformamide 0.80 mL (8 v / w) ) Twice, finally with MTBE 0.80 mL (8 v / w), and ventilated to dry at room temperature.
- the obtained dry resin (Compound 16) was immersed in 1 mL of a dichloromethane solution of 1% TFA to carry out a resin removal reaction. From the LC A% of the Gly-cap compound (Compound 17) and the target product (Compound 18), the conversion rate was calculated to be 75% (68.9 ⁇ (23.5 + 68.9)).
- the present invention provides a method for efficiently producing a peptide compound containing a sequence having poor reactivity so that the condensation reaction is not achieved when the conventional method is applied.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
1)アミノ酸もしくはペプチドのC末端のカルボキシル基との共有結合の形成(担持工程)、
2)担持アミノ酸もしくはペプチドのN末端アミノ基の脱保護反応に続く、次の配列のアミノ酸との縮合反応、および所望の配列に至るまでのこれら脱保護反応、および縮合反応の繰り返し(伸長工程)、
3)固相合成用樹脂からのペプチドの切断(脱樹脂工程)、とからなる(非特許文献5、6)。
固相法は、目的物が結合した固体の固相合成用樹脂と、脱保護反応、および縮合反応用試薬が溶解した液体の反応液を接触させる工程を含む、固体と液体の二層の反応系で行われる。目的物のペプチドが固相合成用樹脂に結合しているため、各工程間では、固相合成用樹脂の洗浄操作を組み入れるのみで、目的物のペプチドが結合した固相合成用樹脂から、過剰の試薬、および試薬由来の不純物を分離することが可能なため、簡便に逐次的な伸長が実施できる。
〔1〕第一のアミノ酸またはペプチドと、第二のアミノ酸またはペプチドとを、添加剤および縮合剤の存在下で縮合させて縮合体を得る工程を含む、ペプチド化合物を製造する方法であって、
添加剤のモル数が、第二のアミノ酸またはペプチドのモル数よりも少ない、前記方法。
〔2〕第二のアミノ酸またはペプチドに対する添加剤のモル比が0.8以下である、〔1〕に記載の方法。
〔3〕第二のアミノ酸またはペプチドに対する縮合剤のモル比が1.0以上である、〔1〕または〔2〕記載の方法。
〔4〕第二のアミノ酸またはペプチドに対する縮合剤のモル比が1.2~4.0である、〔1〕~〔3〕のいずれかに記載の方法。
〔5〕第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比が10以下である、〔1〕~〔4〕のいずれかに記載の方法。
〔6〕第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比が1~2であって、第二のアミノ酸またはペプチドに対する添加剤のモル比が0.7以下である、〔1〕~〔5〕のいずれかに記載の方法。
〔7〕第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比(第1のモル比)が2以上であって、第二のアミノ酸またはペプチドに対する添加剤のモル比が、第1のモル比-1以下である、〔1〕~〔6〕のいずれかに記載の方法。
〔8〕第一のアミノ酸またはペプチドに対する添加剤のモル比が2.0以下である、〔1〕~〔7〕のいずれかに記載の方法。
〔9〕第一のアミノ酸またはペプチドに対する縮合剤のモル比が1.3以上である、〔1〕~〔8〕のいずれかに記載の方法。
〔10〕第二のアミノ酸またはペプチド、縮合剤、および添加剤のモル比が、第二のアミノ酸またはペプチド:縮合剤:添加剤=約2:約4~6:約1である、〔1〕に記載の方法。
〔11〕第一のアミノ酸またはペプチド、第二のアミノ酸またはペプチド、縮合剤、および添加剤のモル比が、第一のアミノ酸またはペプチド:第二のアミノ酸またはペプチド:縮合剤:添加剤=約1:約2:約4:約1、約1:約2.4:約7.2:約1.2、または約1:約3:約6:約1.5である、〔1〕に記載の方法。
〔12〕添加剤が、Oxyma、HOBt、HOOBt、またはHOAtである、〔1〕~〔11〕のいずれかに記載の方法。
〔13〕縮合剤が、DIC、DCC、EDCI、またはEDCI・HClである、〔1〕~〔12〕のいずれかに記載の方法。
〔14〕添加剤がOxymaである、〔1〕~〔13〕のいずれかに記載の方法。
〔15〕前記ペプチド化合物が前記縮合体であるか、あるいは、前記ペプチド化合物がその構造中に前記縮合体を含む、〔1〕~〔14〕のいずれかに記載の方法。
〔16〕固相法で行われる、〔1〕~〔15〕のいずれかに記載の方法。
〔17〕第一のアミノ酸またはペプチドが、固相合成用樹脂に担持されている、〔1〕~〔16〕のいずれかに記載の方法。
〔18〕固相合成用樹脂が、トリチル系樹脂である、〔17〕に記載の方法。
〔19〕トリチル系樹脂が、CTCレジン、Mmtレジン、またはMttレジンである、〔18〕に記載の方法。
〔20〕第二のアミノ酸またはペプチドのアミノ基が、保護基で保護されている、〔1〕~〔19〕のいずれかに記載の方法。
〔21〕保護基が、Fmoc骨格を有する保護基である、〔20〕に記載の方法。
〔22〕前記工程が、DMF、NMP、DMI、テトラヒドロフラン、2-メチルテトラヒドロフラン、酢酸エチル、ジメチルカーボネート、およびアセトニトリルからなる群から選択される溶媒中で行われる、〔1〕~〔21〕のいずれかに記載の製造方法。
〔23〕固相合成用樹脂を除去する工程をさらに含む、〔17〕~〔22〕のいずれかに記載の方法。
〔24〕保護基を除去する工程をさらに含む、〔20〕~〔23〕のいずれかに記載の方法。
〔25〕第一のアミノ酸、または第一のペプチドのN末端のアミノ酸、および/もしくは第一のペプチドのC末端のアミノ酸が、N-アルキルアミノ酸である、〔1〕~〔24〕のいずれかに記載の方法。
〔26〕第一のアミノ酸、または第一のペプチドのC末端のアミノ酸が、N-アルキルβアミノ酸である、〔24〕に記載の方法。
〔27〕第一のアミノ酸、または第一のペプチドのN末端のアミノ酸、および/もしくは第一のペプチドのC末端のアミノ酸が以下の式で表される、〔25〕に記載の方法:
式中、
第一のアミノ酸、または第一のペプチドのN末端のアミノ酸が、式(1)で表されるアミノ酸である場合、R11は水素であり、第一のペプチドのC末端のアミノ酸が、式(1)で表されるアミノ酸である場合、R11は隣接するアミノ酸との結合点を意味し、
P11は水素またはC1-C6アルキルであり、かつR12は水素、CONR12AR12B、COOR12c、C1-C6アルキル、C3-C8シクロアルキル、C7-C14アラルキル、5~10員ヘテロアリールC1-C6アルキル、保護5~10員ヘテロアリールC1-C6アルキル、C1-C6ヒドロキシアルキル、保護C1-C6ヒドロキシアルキル、C1-C6カルボキシアルキル、保護C1-C6カルボキシアルキル、C1-C6アミノアルキル、保護C1-C6アミノアルキル、C1-C6アルキルチオC1-C6アルキルであるか、あるいは
P11およびR12は、P11が結合している窒素原子およびR12が結合している炭素原子と一緒になって4~7員飽和複素環を形成し、
Q12は水素、またはC1-C6アルキルであり
R12AおよびR12Bは、独立して、C1-C4アルキルであるか、あるいは
R12AおよびR12Bはそれらが結合している窒素原子と一緒になって、1つまたは複数の追加のヘテロ原子を含んでいてもよい4~8員環を形成し、
L11は単結合または-CH2-であり、
第一のアミノ酸、または第一のペプチドのC末端のアミノ酸が、式(1)で表されるアミノ酸である場合、R13は固相合成用樹脂との結合点を意味し、第一のペプチドのN末端のアミノ酸が、式(1)で表されるアミノ酸である場合、R13は隣接するアミノ酸との結合点を意味する。
〔28〕第一のアミノ酸、または第一のペプチドのN末端のアミノ酸、および/もしくは第一のペプチドのC末端のアミノ酸が、MeAsp-pip、MeAsp-aze、MeAsp-pyrro、MeAsp-mor、MeAsp-mor(26-bicyc)、MeAsp-OtBu、MeAsp-NMe2、MeVal、MeGly、MeAla、MeLeu、D-3-MeAbu、bMeAla、MeIle、MeGly(cPent)、MeChg、MePhe、MeTrp(Boc)、MeThr(Bzl)、MeGlu(OtBu)、MeLys(Boc)、MeMet、Aze(2)、またはAibである、〔27〕に記載の方法。
〔29〕第二のアミノ酸、または第二のペプチドのC末端のアミノ酸が、α,α-ジ置換アミノ酸、β-分岐アミノ酸、N-アルキルアミノ酸、またはその他の炭素数2以上の側鎖を有するアミノ酸である、〔1〕~〔28〕のいずれかに記載の方法。
〔30〕β-分岐アミノ酸が、以下の式で表される、〔29〕に記載の方法:
式中、
P21は水素またはC1-C6アルキルであり、
R21およびR22はそれぞれ独立して、C1-C4アルキル、C1-C6アルコキシ、またはC1-C6アルコキシC1-C6アルキルであるか、あるいは、R21およびR22はこれらが結合する炭素と一緒になって、3~8員脂環式環を形成し、
第二のアミノ酸が、式(2A)で表されるアミノ酸である場合、R23はアミノ基の保護基との結合点を意味し、第二のペプチドのC末端のアミノ酸が、式(2A)で表されるアミノ酸である場合、R23は隣接するアミノ酸との結合点を意味する。
〔31〕β-分岐アミノ酸が、MeVal、D-MeVal、Val、Ile、MeIle、MeChg、Chg、MeGly(cPent)、Gly(cPent)、MeGly(cBu)、Gly(cBu)、MeGly(cPr)、Gly(cPr)、MeThr(tBu)、またはThr(tBu)である、〔30〕に記載の方法。
〔32〕α,α-ジ置換アミノ酸が、以下の式で表される、〔29〕に記載の方法:
式中、
P22は水素またはC1-C6アルキルであり、
R23およびR24は、C1-C6アルキル、C2-C6アルケニル、または置換されていてもよいC7-C14アラルキルから独立して選択されるか、あるいは
R23およびR24は、それらが結合している炭素原子と一緒になって3~8員脂環式環または4~7員飽和複素環を形成し、
第二のアミノ酸が、式(2B)で表されるアミノ酸である場合、R25はアミノ基の保護基との結合点を意味し、第二のペプチドのC末端のアミノ酸が、式(2B)で表されるアミノ酸である場合、R25は隣接するアミノ酸との結合点を意味する。
〔33〕α,α-ジ置換アミノ酸が、Aib、(Me)Abu、(Me)Leu、(Me)Algly、(Me)Phe、(Me)Phe(3-I)、1-ACPrC、cVal、cLeu、cHex、またはAthpcである、〔32〕に記載の方法。
〔34〕第二のアミノ酸、または第二のペプチドのC末端のアミノ酸が、N-アルキルアミノ酸である、〔1〕~〔33〕のいずれかに記載の方法。
〔35〕N-アルキルアミノ酸が、MeAsp-pip、MeAsp-aze、MeAsp-pyrro、MeAsp-mor、MeAsp-mor(26-bicyc)、MeAsp-OtBu、D-3-MeAbu、bMeAla、MeGly、MeAla、MeLeu、MePhe、Aze(2)、Pro、MeAsp-NMe2、MeVal、MeIle、MeChg、MeGly(cPent)、MeGly(cBu)、MeGly(cPr)、MeThr(tBu)、D-MeVal、MeTrp(Boc)、MeThr(Bzl)、MeGlu(OtBu)、MeLys(Boc)、またはMeMetである、〔34〕に記載の方法。
〔36〕その他の炭素数2以上の側鎖を有するアミノ酸が、Lys(Z)、Glu(OBzl)、またはSer(tBu)である、〔29〕に記載の方法。
〔37〕〔1〕~〔36〕のいずれかに記載の方法によってペプチド化合物を得る工程、および
該ペプチド化合物を環化する工程
を含む、環状ペプチド化合物の製造方法。
A%:area%
Alloc:アリルオキシカルボニル
Aze:アゼチジノ
Boc:tert-ブトキシカルボニル
Cbz: ベンジルオキシカルボニル
COMU:(1-シアノ-2-エトキシ-2-オキソエチリデンアミノオキシ)ジメチルアミノ-モルホリノ-カルベニウムヘキサフルオロリン酸塩
CTC:2-クロロトリチル
CTCレジン:Cl-Trt(2-Cl)レジン
DCC:N,N’-ジシクロヘキシルカルボジイミド
DCM:ジクロロメタン
DIC:N,N’-ジイソプロピルカルボジイミド
DMA:N,N-ジメチルアセトアミド
DMF:N,N-ジメチルホルムアミド
DMI:1,3-ジメチル-2-イミダゾリジノン
EDCI:1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド
Fmoc:9-フルオレニルメチルオキシカルボニル
HATU:O-(7-アザベンゾトリアゾール-1-イル)-N,N,N',N'-テトラメチルウロニウムヘキサフルオロリン酸塩
HMDS:1,1,1,3,3,3-ヘキサメチルジシラザン
HOAt:1-ヒドロキシ-7-アザベンゾトリアゾール
HOBt:1-ヒドロキシベンゾトリアゾール
HPLC:高速液体クロマトグラフィー
iPr2NEt:N,N-ジイソプロピルエチルアミン
K-Oxyma:(ヒドロキシイミノ)シアノ酢酸エチル、カリウム塩
MeCN:アセトニトリル
MeOH:メタノール
2-MeTHF:2-メチルテトラヒドロフラン
Mmtレジン:4-メトキシトリチルクロリドレジン
Mor:モルホリノ
MTBE:メチルtert-ブチルエーテル
Mttレジン:4-メチルトリチルクロリドレジン
NMP:N-メチル-2-ピロリドン
Oxyma:(ヒドロキシイミノ)シアノ酢酸エチル
PDA:フォトダイオードアレー検出器
Pip:ピペリジノ
Pyrro:ピロリジノ
t-Bu:t-ブチル
Teoc:2-(トリメチルシリル)エトキシカルボニル
TFA:トリフルオロ酢酸
TMSOTf:トリフルオロメタンスルホン酸トリメチルシリル
TMU:テトラメチル尿素
TOTU:O-[(エトキシカルボニル)シアノメチレンアミノ]-N,N,N',N'-テトラメチルウロニウムテトラフルオロボラート
本明細書における「ハロゲン原子」としては、F、Cl、BrまたはIが例示される。
(i) A、(ii) B、(iii) C、(iv) AおよびB、(v) AおよびC、(vi) BおよびC、(vii) A、B、およびC。
本発明は、第一のアミノ酸またはペプチドと、第二のアミノ酸またはペプチドとを、添加剤および縮合剤の存在下で縮合させて縮合体を得る工程を含む、ペプチド化合物を製造する方法であって、添加剤のモル数が、第二のアミノ酸またはペプチドのモル数よりも少ない方法に関する。
したがって、本発明の方法では、第一のアミノ酸またはペプチドの固相合成用樹脂に対する担持量として、任意の量、例えばFmoc定量法に基づき、0.2 mmol/g以上、0.8 mmol/g以下の量を用いることができ、0.3 mmol/g以上、さらには0.5 mmol/g以上の高い担持量でも反応を効率的に進行させることができる。
(式中、
R1~R8は、独立して、水素、C1-C8アルキル、C1-C8フルオロアルキル、ハロゲン、スルホ、およびトリメチルシリルからなる群より選択され、
R9~R10は、独立して、水素またはメチルである)。
R21およびR22が一緒になって3~8員脂環式環を形成する場合、3~8員脂環式環として好ましくはシクロプロパン環、シクロブタン環、シクロペンタン環、またはシクロヘキサン環である。
R23およびR24がC1-C6アルキルである場合、好ましくはメチル、エチル、またはイソプロピルであり、R23およびR24がC2-C6アルケニルである場合、好ましくはアリルであり、R23およびR24がC7-C14アラルキルである場合、好ましくはハロゲンで置換されていてもよいベンジルである。R23およびR24の組み合わせは、メチルとメチル、メチルとエチル、メチルとイソプロピル、メチルとイソブチル、メチルとアリル、メチルとハロゲンで置換されていてもよいベンジルが好ましい。
またR23およびR24は、それらが結合している炭素原子と一緒になって3~8員脂環式環を形成する場合、脂環式環として好ましくは、シクロプロパン環、シクロブタン環、シクロペンタン環、またはシクロヘキサン環であり、R23およびR24は、それらが結合している炭素原子と一緒になって4~7員飽和複素環を形成する場合、飽和複素環として好ましくはテトラヒドロピラン環である。
あるいは本発明においては、第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比が1~2の場合、第二のアミノ酸またはペプチドに対する添加剤のモル比は、0.1、0.2、0.3、0.4、0.5、および0.6からなる群より選択される下限、並びに0.2、0.3、0.4、0.5、0.6、および0.7からなる群より選択される上限との組み合わせによって特定することが可能な範囲とすることができる。
あるいは本発明においては、第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比が2以上の場合、第二のアミノ酸またはペプチドに対する添加剤のモル比は、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-9、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-8、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-7、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-6、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-5、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-4、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-3および(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-2からなる群より選択される下限、および(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-8、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-7、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-6、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-5、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-4、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-3、(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-2および(第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比)-1からなる群より選択される上限との組み合わせによって特定することが可能な範囲とすることができる。
あるいは本発明においては、第一のアミノ酸またはペプチドに対する縮合剤のモル比は、1.0、1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8、1.9、2.0、2.1、2.2、2.3、2.4,2.5、2.6、2.7、2.8、2.9、3.0、3.1、3.2、3.3、3.4,3.5、3.6、3.7、3.8、3.9、4.0、4.1、4.2、4.3、4.4,4.5、4.6、4.7、4.8、4.9、5.0、5.1、5.2、5.3、5.4,5.5、5.6、5.7、5.8、5.9、6.0、6.1、6.2、6.3、6.4,6.5、6.6、6.7、6.8、6.9、7.0、7.1、7.2、7.3、7.4,7.5、7.6、7.7、7.8、7.9、8.0、8.1、8.2、8.3、8.4,8.5、8.6、8.7、8.8、8.9、および9.0からなる群より選択される下限、並びに2.1、2.2、2.3、2.4,2.5、2.6、2.7、2.8、2.9、3.0、3.1、3.2、3.3、3.4,3.5、3.6、3.7、3.8、3.9、4.0、4.1、4.2、4.3、4.4,4.5、4.6、4.7、4.8、4.9、5.0、5.1、5.2、5.3、5.4,5.5、5.6、5.7、5.8、5.9、6.0、6.1、6.2、6.3、6.4,6.5、6.6、6.7、6.8、6.9、7.0、7.1、7.2、7.3、7.4,7.5、7.6、7.7、7.8、7.9、8.0、8.1、8.2、8.3、8.4,8.5、8.6、8.7、8.8、8.9、9.0、9.1、9.2、9.3、9.4,9.5、9.6、9.7、9.8、9.9、および10.0からなる群より選択される上限との組み合わせによって特定することが可能な範囲とすることができる。
第一のアミノ酸またはペプチドに対する縮合剤のモル比は、1.3以上であることが好ましく、2.0以上であることがより好ましい。また、第一のアミノ酸またはペプチドに対する縮合剤のモル比は、10以下であることが好ましく、8.0以下であることがより好ましい。第一のアミノ酸またはペプチドに対する縮合剤のモル比としては、約4であることが最も好ましい。
第二のアミノ酸またはペプチドに対する縮合剤のモル比を、1.0、1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8、1.9、および2.0からなる値より選択される下限、並びに2.0、2.1、2.2、2.3、2.4、2.5、2.6、2.7、2.8、2.9、および3.0からなる値より選択される上限との組み合わせによって特定することが可能な範囲とすることができ、
第二のアミノ酸またはペプチドに対する添加剤のモル比を、0.01、0.02、0.03、0.04、0.05、0.06、0.07、0.08、0.09、0.1、0.2、0.3、0.4、および0.5からなる値より選択される下限、並びに0.6、0.7、0.8、0.9および1.0からなる値より選択される上限との組み合わせによって特定することが可能な範囲とすることができる。
第二のアミノ酸またはペプチドに対する縮合剤および添加剤のモル比として、好ましくは、第二のアミノ酸またはペプチド:縮合剤:添加剤=約2:約4~6:約1である。
第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比を、1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8、1.9、2.0、2.1、2.2、2.3、2.4、2.5、2.6、2.7、2.8、2.9および3.0からなる値より選択される下限、並びに2.1、2.2、2.3、2.4、2.5、2.6、2.7、2.8、2.9、3.0、3.1、3.2、3.3、3.4,3.5、3.6、3.7、3.8、3.9、および4.0からなる値より選択される上限との組み合わせによって特定することが可能な範囲とすることができ、
第一のアミノ酸またはペプチドに対する縮合剤のモル比を、1.0、2.0、3.0および4.0からなる値より選択される下限、並びに5.0、6.0、7.0、8.0および9.0からなる値より選択される上限との組み合わせによって特定することが可能な範囲とすることができ、
第一のアミノ酸またはペプチドに対する添加剤のモル比を、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9および1.0からなる値より選択される下限、並びに1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8、1.9、2.0、2.1、2.2、2.3、2.4、2.5、2.6、2.7、2.8、2.9および3.0からなる値より選択される上限との組み合わせによって特定することが可能な範囲とすることができる。
第一のアミノ酸またはペプチド、第二のアミノ酸またはペプチド、縮合剤、および添加剤のモル比として好ましくは、第一のアミノ酸またはペプチド:第二のアミノ酸またはペプチド:縮合剤:添加剤=約1:約2:約4:約1、第一のアミノ酸またはペプチド:第二のアミノ酸またはペプチド:縮合剤:添加剤=、約1:約2.4:約7.2:約1.2、または第一のアミノ酸またはペプチド:第二のアミノ酸またはペプチド:縮合剤:添加剤=約1:約3:約6:約1.5であり、より好ましくは第一のアミノ酸またはペプチド:第二のアミノ酸またはペプチド:縮合剤:添加剤=約1:約2:約4:約1である。
HPLC method A
Instrument: ACQUITY UPLC H-Class
Column: Ascentis Express C18 (2.7 μm, 4.6 mm x 50 mm), Supelco
Column temperature: 35 deg.
Eluent: A) 0.05% TFA/water, B) 0.05% TFA/MeCN
Gradient (B): 5% (0 min.) → 100% (4 min.) → 100% (4.5 min.) → 5% (4.6 min.) → 5% (6 min.)
Flow rate: 1.0 mL/min
Detection: PDA 210 nm (200-400 nm PDA total)
Injection volume: A-a) 0.30 μL, A-b) 1.0 μL, A-c) 2.0 μL
Sample preparation:
A-a) 5 μL of supernatant / 995 μL MeCN for loading evaluation
A-b) 5 μL of supernatant / 995 μL MeCN for loading evaluation
A-c) 40 μL of supernatant / 960 μL MeCN for Gly-cap evaluation
Instrument: ACQUITY UPLC H-Class
Column: CAPCELL Core ADME (2.7 μm, 2.1 mm x 50 mm)
Column temperature: 50 deg.
Eluent: A) 0.05% TFA/water, B) 0.05% TFA/MeCN
Gradient (B): 30% (0 min.) → 70% (20.0 min.) → 100% (20.1 min.) → 100% (22.0 min.) → 30% (22.1 min.) → 30% (24.0 min.)
Flow rate: 0.3 mL/min
Detection: PDA 210 nm (200-400 nm PDA total)
Injection volume: 1.0 μL
Sample preparation: 40 μL of supernatant / 960 μL MeCN
Instrument: ACQUITY UPLC H-Class
Column: ACQUITY UPLC CSH Fluoro-Phenyl (1.7 μm, 2.1 mm x 150 mm)
Column temperature: 35 deg.
Eluent: A) 0.1% formic acid/water, B) 0.1% formic acid/MeCN
Gradient (B): 5% (0 min.) → 100% (15.0 min.) → 100% (18.0 min.) → 5% (18.01 min.) → 5% (20.0 min.)
Flow rate: 0.3 mL/min
Detection: PDA 254 nm (200-380 nm PDA total)
Injection volume: 2.0 μL
Sample preparation: 0.37 mg/ml
Instrument: ACQUITY UPLC H-Class
Column: Bioshell A160 peptide (2.7 μm, 2.1 mm x 150 mm)
Column temperature: 40 deg.
Eluent: A) 0.05% TFA/water, B) 0.05% TFA/MeCN
Gradient (B): 20% (0 min.) → 60% (20 min.) → 100% (20.1 min.) → 100% (22.0 min.) → 100% (22.1 min.) → 20% (24 min.)
Flow rate: 0.5 mL/min
Detection: PDA 254 nm
Injection volume: 2.0 μL
Sample preparation: 5 μL of supernatant / 1000 μL MeCN
Instrument: Acquity UPLC/SQD2
Column: Ascentis Express C18
Column temperature: 35 deg.
Eluent: A) 0.1% FA/water, B) 0.1% FA/acetonitrile
Gradient (B): 5% (0 min.) → 100% (1.0 min.) → 100% (1.4 min.)
Flow rate: 1.0 mL/min
Detection: PDA 210-400 nm(total)
Instrument: Acquity UPLC/SQD2
Column: Ascentis Express C18
Column temperature: 35 deg.
Eluent: A) 0.1% FA/water, B) 0.1% FA/acetonitrile
Gradient (B): 5% (0 min.) → 100% (4.5 min.) → 100% (5.0 min.)
Flow rate: 1.0 mL/min
Detection: PDA 210-400 nm(total)
Instrument: Acquity UPLC/SQD2
Column: Ascentis Express C18
Column temperature: 35 deg.
Eluent: A) 10mM AA/water, B) methanol
Gradient (B): 50% (0 min.) → 100% (4.5 min.) → 100% (5.0 min.)
Flow rate: 1.0 mL/min
Detection: PDA 210-400 nm(total)
Instrument: ACQUITY UPLC H-Class
Column: Ascentis Express RP-amide (2.7 μm, 2.1 mm x 50 mm), Supelco
Column temperature: 35 deg.
Eluent: A) 0.05% TFA/water, B) 0.05% TFA/MeCN
Gradient (B): 5% (0 min.) → 100% (4 min.) → 100% (4.5 min.) → 5% (4.6 min.) → 5% (6 min.)
Flow rate: 0.5 mL/min
Detection: PDA 210 nm (200-400 nm PDA total)
Injection volume: E-a) 0.50 μL, E-b) 0.50 μL, E-c) 1.0 μL
Sample preparation:
E-a) 5 μL of supernatant / 960 μL MeCN for Gly-cap evaluation or purity evaluation
Instrument: ACQUITY UPLC H-Class
Column: Ascentis Express RP-amide (2.7 μm, 2.1 mm x 50 mm), Supelco
Column temperature: 50 deg.
Eluent: A) 0.05% TFA/water, B) 0.05% TFA/MeCN
Gradient (B): 5% (0 min.) → 70% (20 min.) → 70% (21 min.) → 100% (22 min.) → 100% (22.1 min.) → 5% (22.6 min.) → 5% (24.0 min.)
Flow rate: 0.5 mL/min
Detection: PDA 210 nm (200-400 nm PDA total)
Injection volume: 0.50 or 1.0 μL
Sample preparation: 40 μL of supernatant / 960 μL MeCN
Instrument: ACQUITY UPLC H-Class
Column: ACQUITY UPLC CSH Fluoro-Phenyl (1.7 μm, 2.1 mm x 150 mm)
Column temperature: 40 deg.
Eluent: A) 0.05% TFA/water, B) 0.05% TFA/MeCN
Gradient (B): 20% (0 min.) → 100% (20 min.) → 20% (20.1 min.) → 12% (24.0 min.)
Flow rate: 0.3 mL/min
Detection: PDA 254 nm (200-400 nm PDA total)
Injection volume: 1.0 μL
Sample preparation: 40 μL of supernatant / 960 μL MeCN
[出発原料合成]
(出発原料合成1)
Fmoc-MeAsp(OtBu)-pip (化合物2)の合成
500 mLの3径フラスコにFmoc-MeAsp(OtBu)-OH (化合物1)を26.9 g (63.2 mmol, 1.0 eq)、ピペリジン塩酸塩を9.23 g (75.9 mmol, 1.2 eq)、Oxymaを10.8 g (69.5 mmol, 1.1 eq)、N,N-ジメチルホルムアミドを135 mL加え、撹拌した。滴下漏斗を用いて1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミドを12.2 mL (69.5 mmol, 1.1 eq)、0 ℃で10分間かけて滴下した。滴下後、N,N-ジメチルホルムアミド1.25 mLを用いて滴下漏斗を二度洗浄した。反応開始5時間後、2-MeTHF 269 mLを加えた後、10分かけて0.5 mol/L塩酸水溶液 135 mLを加えた。水層を排出した後、有機層に5%炭酸ナトリウム水溶液135 mLを加えた。水層を排出した後、有機層に10%塩化ナトリウム水溶液135 mLを加えた。水層を排出した後、有機層を室温で一晩保管した。約60 mlの有機溶媒を減圧留去後、濃縮液に室温で酢酸エチルを81 mL加えた。撹拌しながらヘプタンを323 mL加えた。外温を0 ℃に設定し、1時間20分後、ヘプタンを161 ml加えた。桐山ロートを用い結晶を濾別洗浄後、得た結晶を外温40 ℃で減圧乾燥し白色固体28.2 g (化合物2)を得た。
Fmoc-MeAsp(OH)-pip (化合物3)の合成
100 mLの3径ナスフラスコにFmoc-MeAsp(OtBu)-pip (化合物2)を1.58 g (3.20 mmol, 1.0 eq)秤量後、窒素雰囲気下で2-MeTHFを9.5 mLシリンジで加え撹拌し、HMDSを1.0 mL (4.8 mmol, 1.5 eq)シリンジで加えた。フラスコを氷浴に浸し、内温が1℃となった時にTMSOTfを0.79 mL (4.4 mmol, 1.4 eq)シリンジで加えた。滴下終了5分後に室温へと昇温し、1時間後、HPLC(method A-a)で反応率が100%であることを確認した。反応容器を再び氷浴に浸し、内温が5℃に達した時に5%炭酸ナトリウム水溶液を15 mL加えた。炭酸ナトリウム水溶液を加え終えてから数分間反応溶液を撹拌後、撹拌を停止した。反応容器を50 mL分液漏斗に移し分層後、水層を分取した。得た水層をMTBE 15 mLで洗浄した。分取した水層にMTBEを15 mL加えた後、リン酸(質量分率85%以上)を1.1 mL加えた。分液漏斗で溶液を振盪後、分層し有機層を分取した。得た有機層に硫酸マグネシウムを加えた後、硫酸マグネシウムを濾過した。濾液にヘプタンを1.5 mL加え、減圧濃縮を行い白色固体1.42 g (化合物3)を得た(含量未測定)。
LCMS(ESI) m/z = 437.2 (M+H)+
保持時間:0.86分(分析条件 HPLC METHOD E)
LCMS(ESI) m/z = 397.2 (M+H)+
保持時間:0.68分(分析条件 HPLC METHOD E)
本明細書では、固相支持体と化合物が結合した場合、ポリマーや樹脂部位を●で表記する場合がある。また、固相支持体部位との反応点を明確にさせる目的で、●に接続させて反応部位であるリンカーの化学構造を表記させる場合がある。例えば、下記の構造(Fmoc-MeAsp(O-Trt(2-Cl)-resin)pip (化合物3)では、固相支持体の2-クロロトリチル基がMeAspの側鎖カルボキシ基とエステル結合を形成している。なお、pipとはピペリジノ基を意味し、上記の構造では、C末端のカルボキシ基がピペリジンとアミド結合を形成している。
本明細書では、固相反応実施時の溶媒量を倍量(v/w)で表記する場合がある。倍量の基準は、担持工程のCl-Trt(2-Cl) レジンの質量であり、例えば固相原料合成1において、3.97 gのCl-Trt(2-Cl) レジンに対し、ジクロロメタンを40 mL用いた場合、40/3.97 ≒ 10 v/wとなる。また、1残基+1残基縮合実験では、担持工程で得られた樹脂中間体を小分けして使用した。1残基+1残基縮合実験時の溶媒量は4 v/wであるが、これを体積換算すると、4 (mL/g) x 小分け樹脂 (g) ÷ 担持後の樹脂 (g) x 担持工程原料樹脂 (g) = 4 (mL/g) x 小分け樹脂 (g) / 5.79 x 3.97 mLに相当する。
測定溶液のモル濃度(mol/L) = 吸光度 ÷ ε
Fmoc定量値(mmol/g) = 測定溶液のモル濃度(mol/L) ÷ 測定用樹脂(g) × 100 (mL)
Fmoc定量法(実施例2-2~実施例2-11)
市販のFmoc-Gly-OH約10 mgを10 mLメスフラスコに秤量した後、DMF (4 ml)を加えた。30分間室温で振盪した後、DBU (40 μL)を加え、この溶液を15分間室温で振盪した。 その後、DMFを加え10 mLになるようにメスアップした。溶液上清30 μLと4 mlのDMF溶液からサンプル液を調製し、LCデータを取得した(5 μL injection)。取得データから294 nmおよび304 nmの各波長で検量線を作成した。
(固相原料合成1)
Fmoc-MeAsp(OH)-pip (化合物3)のTrt(2-Cl)レジンへの担持
固相反応用カラムにCl-Trt(2-Cl)レジンを3.97 g (1.36 mmol/g, 5.40 mmol, 1.7 eq)秤量し、ジクロロメタンを40 mL (10 v/w)加え30分間室温で静置させた。ジクロロメタンを排出後、Fmoc-MeAsp(OH)-pip (化合物3)を1.40 g (3.20 mmol, 1.0 eq)およびN,N-ジイソプロピルエチルアミン1.6 mL (9.0 mmol, 2.8 eq)をジクロロメタン30 mL (7.5 v/w)に溶解させた溶液を室温にて反応用カラムに加えた後、室温で2時間振盪させた。反応溶液を排出後、メタノール3.2 mL (0.8 v/w)とN,N-ジイソプロピルエチルアミン1.6 mL (0.4 v/w)をN,N-ジメチルホルムアミド27 mL (6.8 v/w)に溶解させた溶液を室温にて反応用カラムに加えた。室温で2時間振盪させた後、反応溶液を排出した。樹脂をN,N-ジメチルホルムアミド40 mL (10 v/w)で4回、次に2-プロパノール40 mL (10 v/w)で2回、続いてメタノール40 mL (10 v/w)で4回洗浄した後、終夜室温にて減圧乾燥し、5.79 gの乾燥樹脂(化合物4)を得た。得られた樹脂を100 mLメスフラスコに19.4 mg量り取り、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液でメスアップし45分室温で振盪した。分光光度計を用いて溶液の吸光度からFmoc定量を行い、得られたFmoc定量値と乾燥樹脂の質量とLC A%から収率を算出した。
Fmoc-MeLeu-OH (化合物37)のTrt(2-Cl)レジンへの担持
固相反応用カラムにCl-Trt(2-Cl)レジンを1.01 g (1.13 mmol/g, 1.14 mmol, 1.4 eq)秤量し、ジクロロメタンを10 mL (10 v/w)加え30分間室温で静置させた。ジクロロメタンを排出後、Fmoc-MeLeu-OH (化合物1)を0.29 g (0.79 mmol, 1.0 eq)およびN,N-ジイソプロピルエチルアミン0.40 mL (2.3 mmol, 2.9 eq)をジクロロメタン8.0 mL (8 v/w)に溶解させた溶液を室温にて反応用カラムに加えた後、室温で2時間振盪させた。反応溶液を排出後、メタノール0.80 mL (0.8 v/w)とN,N-ジイソプロピルエチルアミン0.40 mL (0.4 v/w)をN,N-ジメチルホルムアミド 6.8 mL (6.8 v/w)に溶解させた溶液を室温にて反応用カラムに加えた。室温で2時間振盪させた後、反応溶液を排出した。樹脂をN,N-ジメチルホルムアミド 10 mL (10 v/w)で4回、次に2-プロパノール10 mL (10 v/w)で2回、続いてメタノール10 mL (10 v/w)で4回洗浄した後、終夜室温にて減圧乾燥し、1.27 gの乾燥樹脂 (化合物38)を得た。得られた樹脂を100 mLメスフラスコに17.7 mg量り取り、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液でメスアップし45分室温で振盪した。分光光度計を用いて溶液の吸光度からFmoc定量を行い、得られたFmoc定量値と乾燥樹脂の質量とLC A%から収率を算出した。
[実施例1]
(1残基+1残基縮合実験)
Fmoc-MeVal-MeAsp(OCTC)-pip (化合物5)の合成(レジンのアミノ酸に対し、Fmocアミノ酸:DIC:添加剤(Oxyma)=2:4:1の反応条件:以降、実施例条件Aと呼ぶ)
固相反応用カラムに乾燥樹脂 (化合物4)を3.01 g (0.525 mmol/g, 1.57 mmol, 1.0 eq)秤量し、N,N-ジメチルホルムアミドを21 mL (10 v/w)加え30分間室温で静置させた。N,N-ジメチルホルムアミドを排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を17 mL (8 v/w)を加え室温で15分間振盪させた。反応溶液を排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を17 ml (8 v/w)を再び加え室温で15分間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 21 mL (10 v/w)で8回洗浄した。次にバイアルにFmoc-MeVal-OH 1.12 g (3.16 mmol, 2.0 eq)とOxyma 0.226 g (1.58 mmol, 1.0 eq)を秤量し、N,N-ジメチルホルムアミドを 8.2 mL (4 v/w)を加え溶解させ、本溶液を固相合成用カラムに加えた。続けてDIC を0.99 mL (6.3 mmol, 4.0 eq)加え、密封後室温にて6時間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 21 mL (10 v/w) で4回、次に2-プロパノール21 mL (10 v/w)で2回、続いてメタノール21 mL (10 v/w)で4回洗浄した後、終夜室温にて減圧乾燥し、2.78 gの乾燥樹脂 (化合物5)を得た。得られた樹脂を100 mLメスフラスコに23.2 mg秤量し、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液でメスアップし45分室温で振盪した。分光光度計を用いて溶液の吸光度からFmoc定量を行い、得られたFmoc定量値と乾燥樹脂の質量とLC A%から収率を算出した。
Fmoc-D-MeVal-MeAsp(OCTC)-pip (化合物10)の合成(実施例条件Aによる合成)
フィルター付きの5 mLディスポーザブルシリンジに乾燥樹脂 (化合物4)を0.195 g (0.525 mmol/g, 0.101 mmol, 1.0 eq)秤量し、N,N-ジメチルホルムアミドを1.3 mL (10 v/w)加え30分間室温で静置させた。N,N-ジメチルホルムアミドを排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.1 mL (8 v/w)を加え室温で15分間振盪させた。反応溶液を排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.1 mL (8 v/w)再び加え室温で15分間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 1.3 mL (10 v/w)で8回洗浄した。次にバイアルにFmoc-D-MeVal-OH 72 mg (0.21 mmol, 2.0 eq)とOxyma 15 mg (0.11 mmol, 1.0 eq)を秤量し、N,N-ジメチルホルムアミド を0.54 mL (4 v/w)加え溶解させ、この溶液をディスポーザブルシリンジで吸引した。続いてDIC を66 μL (0.42 mmol, 4 eq)加え、密封後室温にて6時間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 1.3 mL (10 v/w) で4回、次に2-プロパノール1.3 mL (10 v/w)で2回、続いてメタノール1.3 mL (10 v/w)で4回洗浄した後、終夜室温にて減圧乾燥し、0.188 gの乾燥樹脂 (化合物10)を得た。得られた樹脂を100 mLメスフラスコに22.6 mg秤量し、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液でメスアップし45分室温で振盪した。分光光度計を用いて溶液の吸光度からFmoc定量を行い、得られたFmoc定量値と乾燥樹脂の質量とLC A%から収率を算出した。
目的とするペプチドを構成するFmocアミノ酸(第二のアミノ酸)、添加剤としてHOAtもしくはOxyma、およびNMPを用いて、Fmocアミノ酸の濃度が0.6 mol/Lに、添加剤の濃度が0.375 mol/Lとなるように溶解させて溶液1を調製した。Fmocアミノ酸が難溶の場合、20~30%(v/v)となるようDMSOを添加して溶液1を調製した。また、DICが10%(v/v)となるようにDMFと混合し、溶液2を調製した。固相原料合成1~4にて調製したFmocアミノ酸もしくはペプチドが担持されたレジン(100 mg)をフィルター(フリット)付の固相反応容器に入れてペプチド合成機にセットした。DCM(1.2 mL)を加えて30分間静置することでレジンの膨潤を行った後、溶液をフリットから排出した。溶液1および溶液2をペプチド合成機にセットし、ペプチド合成機による自動合成を開始した。
実施例2では回収率を以下のように定義した。回収率が高いほど、premature cleavageは抑制されたことになる。
回収率 = 伸長反応後の実際のFmoc定量値(mmol/g) ÷ 伸長反応後の理論的なFmoc定量値(mmol/g)(式1)
伸長反応後の理論的なFmoc定量値(mmol/g)= 原料レジンのFmoc定量値(mmol/g) × 原料レジンの重量(g) ÷ 目的物が100%生成した場合のレジンの重量(g)(式2)
目的物が100%生成した場合のレジンの重量(g) = 原料レジンの重量(g) - 原料レジン上のアミノ酸、もしくはペプチド成分の重量(g) + 目的物が100%生成した場合のレジン上のペプチド成分の重量(g)(式3)
原料レジン上のアミノ酸、もしくはペプチド成分の重量(g) = 原料レジンのFmoc定量値(mmol/g) × 原料レジンの重量(g) × 原料レジンの上のアミノ酸、もしくはペプチド成分の分子量(g/mol) × 0.001(mol/mmol)(式4)
目的物が100%生成した場合のレジン上のペプチド成分の重量(g) = 原料レジンのFmoc定量値(mmol/g) × 原料レジンの重量(g) × 目的物のペプチド成分の分子量(g/mol) × 0.001(mol/mmol)(式5)
伸長反応後の理論的なFmoc定量値(mmol/g) = 原料レジンのFmoc定量値(mmol/g) ÷ (1 - 原料レジンのFmoc定量値(mmol/g) × 原料レジンの上のアミノ酸、もしくはペプチド成分の分子量(g/mol) × 0.001(mol/mmol) + 原料レジンのFmoc定量値(mmol/g) × 目的物のペプチド成分の分子量(g/mol) × 0.001(mol/mmol)) = 1 ÷ (1 ÷ 原料レジンのFmoc定量値(mmol/g) - 原料レジンの上のアミノ酸、もしくはペプチド成分の分子量(g/mol) × 0.001(mol/mmol) + 目的物のペプチド成分の分子量(g/mol) × 0.001(mol/mmol))(式6)
回収率 = 伸長反応後の実際のFmoc定量値(mmol/g) × (1 ÷ 原料レジンのFmoc定量値(mmol/g) - 原料レジンの上のアミノ酸、もしくはペプチド成分の分子量(g/mol) × 0.001(mol/mmol) + 目的物のペプチド成分の分子量(g/mol) × 0.001(mol/mmol))
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeVal-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物27を合成した。乾燥レジン(10.45 mg)を用い、Fmoc定量法により担持率を算出すると、0.292 mmol/gであった(294 nmにおけるUVarea値:3046.82、304 nmにおけるUVarea値:2746.87)。
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeVal-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物27を合成した。乾燥レジン(10.89 mg)を用い、Fmoc定量法により担持率を算出すると、0.332 mmol/gであった(294 nmにおけるUVarea値:3612.81、304 nmにおけるUVarea値:3267.35)。
回収率 = 0.332 × (1 ÷ 0.455 - 436.51 × 0.001 + 662.83 × 0.001) = 80.5%
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeIle-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物28を合成した。乾燥レジン(10.81 mg)を用い、Fmoc定量法により担持率を算出すると、0.326 mmol/gであった(294 nmにおけるUVarea値:3524.40、304 nmにおけるUVarea値:3171.55)。
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeIle-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物28を合成した。乾燥レジン(10.41 mg)を用い、Fmoc定量法により担持率を算出すると、0.330 mmol/gであった(294 nmにおけるUVarea値:3437.60、304 nmにおけるUVarea値:3100.91)。
回収率 = 0.330 × (1 ÷ 0.455 - 436.51 × 0.001 + 676.86 × 0.001) = 80.5%
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeGly(cPent)-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物29を合成した。乾燥レジン(10.05 mg)を用い、Fmoc定量法により担持率を算出すると、0.320 mmol/gであった(294 nmにおけるUVarea値:3216.77、304 nmにおけるUVarea値:2905.18)。
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeGly(cPent)-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物29を合成した。乾燥レジン(9.45 mg)を用い、Fmoc定量法により担持率を算出すると、0.232 mmol/gであった(294 nmにおけるUVarea値:2194.45、304 nmにおけるUVarea値:1975.12)。
回収率 = 0.232 × (1 ÷ 0.455 - 436.51 × 0.001 + 688.87 × 0.001) = 56.8%
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeChg-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物30を合成した。乾燥レジン(9.68 mg)を用い、Fmoc定量法により担持率を算出すると、0.314 mmol/gであった(294 nmにおけるUVarea値:3037.14、304 nmにおけるUVarea値:2743.09)。
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeChg-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物30を合成した。乾燥レジン(9.91 mg)を用い、Fmoc定量法により担持率を算出すると、0.226 mmol/gであった(294 nmにおけるUVarea値:2235.50、304 nmにおけるUVarea値:2016.81)。
回収率 = 0.226 × (1 ÷ 0.455 - 436.51 × 0.001 + 702.89 × 0.001) = 55.7%
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeLeu-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物31を合成した。乾燥レジン(10.74 mg)を用い、Fmoc定量法により担持率を算出すると、0.369 mmol/gであった(294 nmにおけるUVarea値:3953.19、304 nmにおけるUVarea値:3570.96)。
固相原料合成1にて調製したアミノ酸担持レジン(化合物4)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-pip)(100 mg, 0.455 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeLeu-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物31を合成した。乾燥レジン(10.73 mg)を用い、Fmoc定量法により担持率を算出すると、0.337 mmol/gであった(294 nmにおけるUVarea値:3610.72、304 nmにおけるUVarea値:3254.78)。
回収率 = 0.337 × (1 ÷ 0.455 - 436.51 × 0.001 + 676.86 × 0.001) = 82.2%
固相原料合成2にて調製したアミノ酸担持レジン(化合物22)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-NMe2)(100 mg, 0.442 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeGly(cPent)-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物32を合成した。乾燥レジン(10.73 mg)を用い、Fmoc定量法により担持率を算出すると、0.304 mmol/gであった(294 nmにおけるUVarea値:3263.10、304 nmにおけるUVarea値:2945.28)。
固相原料合成2にて調製したアミノ酸担持レジン(化合物22)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-NMe2)(100 mg, 0.442 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeGly(cPent)-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物32を合成した。乾燥レジン(10.60 mg)を用い、Fmoc定量法により担持率を算出すると、0.211 mmol/gであった(294 nmにおけるUVarea値:2239.56、304 nmにおけるUVarea値:2018.13)。
回収率 = 0.211 × (1 ÷ 0.442 - 396.44 × 0.001 + 648.80 × 0.001) = 53.1%
固相原料合成2にて調製したアミノ酸担持レジン(化合物22)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-NMe2)(100 mg, 0.442 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeLeu-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物33を合成した。乾燥レジン(10.15 mg)を用い、Fmoc定量法により担持率を算出すると、0.371 mmol/gであった(294 nmにおけるUVarea値:3770.57、304 nmにおけるUVarea値:3391.62)。
固相原料合成2にて調製したアミノ酸担持レジン(化合物22)(Fmoc-MeAsp(O-Trt(2-Cl)resin)-NMe2)(100 mg, 0.442 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeLeu-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物33を合成した。乾燥レジン(10.73 mg)を用い、Fmoc定量法により担持率を算出すると、0.334 mmol/gであった(294 nmにおけるUVarea値:3587.19、304 nmにおけるUVarea値:3234.07)。
回収率 = 0.334 × (1 ÷ 0.442 - 396.44 × 0.001 + 636.79 × 0.001) = 83.6%
固相原料合成3にて調製したアミノ酸担持レジン(化合物24)(Fmoc-D-3-MeAbu-O-Trt(2-Cl)resin)(100 mg, 0.369 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeVal-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物34を合成した。乾燥レジン(10.62 mg)を用い、Fmoc定量法により担持率を算出すると、0.295 mmol/gであった(294 nmにおけるUVarea値:3138.26、304 nmにおけるUVarea値:2821.05)。
固相原料合成3にて調製したアミノ酸担持レジン(化合物24)(Fmoc-D-3-MeAbu-O-Trt(2-Cl)resin)(100 mg, 0.369 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeVal-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物34を合成した。乾燥レジン(10.44 mg)を用い、Fmoc定量法により担持率を算出すると、0.284 mmol/gであった(294 nmにおけるUVarea値:2964.86、304 nmにおけるUVarea値:2667.78)。
回収率 = 0.284 × (1 ÷ 0.369 - 339.39 × 0.001 + 565.71 × 0.001) = 83.4%
固相原料合成3にて調製したアミノ酸担持レジン(化合物24)(Fmoc-D-3-MeAbu-O-Trt(2-Cl)resin)(100 mg, 0.369 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeChg-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物35を合成した。乾燥レジン(10.20 mg)を用い、Fmoc定量法により担持率を算出すると、0.293 mmol/gであった(294 nmにおけるUVarea値:2987.04、304 nmにおけるUVarea値:2692.68)。
固相原料合成3にて調製したアミノ酸担持レジン(化合物24)(Fmoc-D-3-MeAbu-O-Trt(2-Cl)resin)(100 mg, 0.369 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeChg-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物35を合成した。乾燥レジン(9.56 mg)を用い、Fmoc定量法により担持率を算出すると、0.217 mmol/gであった(294 nmにおけるUVarea値:2072.81、304 nmにおけるUVarea値:1864.82)。
回収率 = 0.217 × (1 ÷ 0.369 - 339.39 × 0.001 + 605.78 × 0.001) = 64.6%
固相原料合成4にて調製したアミノ酸担持レジン(化合物26)(Fmoc-MeGly-O-Trt(2-Cl)resin)(100 mg, 0.573 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeVal-OHの伸長(HOAt、40℃、2.5時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物36を合成した。乾燥レジン(10.20 mg)を用い、Fmoc定量法により担持率を算出すると、0.326 mmol/gであった(294 nmにおけるUVarea値:3322.12、304 nmにおけるUVarea値:3002.34)。
固相原料合成4にて調製したアミノ酸担持レジン(化合物26)(Fmoc-MeGly-(O-Trt(2-Cl)resin))(100 mg, 0.573 mmol/g)を出発原料とし、合成法1に従い、Fmoc-MeVal-OHの伸長(Oxyma、50℃、10時間)、次いでFmoc-Ile-OHの伸長(HOAt、40℃、2.5時間)を行い、化合物36を合成した。乾燥レジン(10.69 mg)を用い、Fmoc定量法により担持率を算出すると、0.331 mmol/gであった(294 nmにおけるUVarea値:3542.66、304 nmにおけるUVarea値:3189.92)。
回収率 = 0.331 × (1 ÷ 0.573 - 311.34 × 0.001 + 537.66 × 0.001) = 65.3%
[実施例2-12]
Fmoc-MeVal-MeLeu-OCTC (化合物39)の合成(実施例条件Aによる合成)
フィルター付きの5 mLディスポーザブルシリンジに乾燥樹脂 (化合物38)を0.195 g (0.650 mmol/g, 0.127 mmol, 1.0 eq)秤量し、N,N-ジメチルホルムアミドを1.6 mL (10 v/w)加え30分間室温で静置させた。N,N-ジメチルホルムアミドを排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.3 mL (8 v/w)を加え室温で15分間振盪させた。反応溶液を排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.3 ml (8 v/w)を再び加え室温で15分間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 1.6 mL (10 v/w)で8回洗浄した。次にバイアルにFmoc-MeVal-OH 90 mg (0.25 mmol, 2.0 eq)とOxyma 18 mg (0.13 mmol, 1.0 eq)を秤量し、N,N-ジメチルホルムアミドを 0.62 mL (4 v/w)を加え溶解させた。この溶液にDIC を80 μL (0.51 mmol, 4.0 eq)加えた後、直ぐにディスポーザブルシリンジで吸引し、密封後室温にて18時間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 1.6 mL (10 v/w) で4回、次に2-プロパノール1.6 mL (10 v/w)で2回、続いてメタノール1.6 mL (10 v/w)で4回洗浄した後、終夜室温にて減圧乾燥し、0.201 gの乾燥樹脂 (化合物39)を得た。得られた樹脂を100 mLメスフラスコに16.7 mg秤量し、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液でメスアップし45分室温で振盪した。分光光度計を用いて溶液の吸光度からFmoc定量を行い、得られたFmoc定量値と乾燥樹脂の質量とLC A%から収率を算出した。
Chem. Eur. J., 2009, 15, 9394-9403に記載の反応条件(レジンのアミノ酸に対し、Fmocアミノ酸:DIC:添加剤(Oxyma)=2:2:2の反応条件:以降、参照例条件Aと呼ぶ)によるFmoc-MeVal-MeLeu-OCTC (化合物39)の合成
フィルター付きの5 mLディスポーザブルシリンジに乾燥樹脂 (化合物38)を0.204 g (0.650 mmol/g, 0.133 mmol, 1.0 eq)秤量し、N,N-ジメチルホルムアミドを1.6 mL (10 v/w)加え30分間室温で静置させた。N,N-ジメチルホルムアミドを排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.3 mL (8 v/w)を加え室温で15分間振盪させた。反応溶液を排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.3 mL (8 v/w)再び加え室温で15分間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 1.6 mL (10 v/w)で8回洗浄した。次にバイアルにFmoc-MeVal-OH 96 mg (0.26 mmol, 2.0 eq)とOxyma 38 mg (0.26 mmol, 2.0 eq)を秤量し、N,N-ジメチルホルムアミド を0.65 mL (4 v/w)加え溶解させた。続いてDIC を42 μl (0.26 mmol, 2.0 eq)バイアルに室温で加えた後、容器を密閉し2分間室温で振盪した。この溶液をディスポーザブルシリンジで吸引し、密封後室温にて18時間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 1.6 mL (10 v/w) で4回、次に2-プロパノール1.6 mL (10 v/w)で2回、続いてメタノール1.6 mL (10 v/w)で4回洗浄した後、終夜室温にて減圧乾燥し、0.181 gの乾燥樹脂 (化合物3)を得た。得られた樹脂を100 mLメスフラスコに19.0 mg秤量し、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液でメスアップし45分室温で振盪した。分光光度計を用いて溶液の吸光度からFmoc定量を行い、得られたFmoc定量値と乾燥樹脂の質量とLC A%から収率を算出した。
[実施例2-13]
Fmoc-D-MeVal-MeLeu-OCTC (化合物41)の合成(実施例条件Aによる合成)
Fmoc-Aze(2)-MeThr(Bzl)-OCTC (化合物53)の合成(実施例条件Aおよび参照例条件Aによる合成)
Premature cleavageの抑制効果を生む試薬当量範囲の探索実験
上記[1残基+1残基縮合実験](実施例条件A)をもとに、試薬当量を変更して同じ反応を実施した結果を以下に示す。
一方、Oxymaの当量を減じると純度、収率が改善した(Entry 4, 8, 13, 16)。
また、DICの当量を増やすと純度、収率が改善した(Entry 5, 6)。
さらにOxymaの当量を減じ、かつDICの当量を増やすと純度、収率が改善した(Entry 2, 9, 10, 11, 12, 14, 15)。
とりわけEntry 2, 9, 10, 11では収率が75%を上回る結果を得た。
Chem. Eur. J., 2009, 15, 9394-9403)のFmoc-MeVal-MeAsp(OCTC)-pip (化合物5)の合成(レジンのアミノ酸に対し、Fmocアミノ酸:DIC:添加剤(Oxyma)=2:2:2の反応条件:参照例条件A)
フィルター付きの5 mLディスポーザブルシリンジに乾燥樹脂(化合物4)を0.200 g (0.525 mmol/g, 0.104 mmol, 1.0 eq)秤量し、N,N-ジメチルホルムアミドを1.3 mL (10 v/w)加え30分間室温で静置させた。N,N-ジメチルホルムアミドを排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.1 mL (8 v/w)を加え室温で15分間振盪させた。反応溶液を排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.1 mL (8 v/w)再び加え室温で15分間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 1.3 mL (10 v/w)で8回洗浄した。次にバイアルにFmoc-MeVal-OH 74 mg (0.21 mmol, 2.0 eq)とOxyma 30 mg (0.21 mmol, 2.0 eq)を秤量し、N,N-ジメチルホルムアミド を0.54 mL (4 v/w)加え溶解させた。続いてDIC を33 μl (0.21 mmol, 2.0 eq)バイアルに室温で加えた後、容器を密閉し2分間室温で振盪した。この溶液をディスポーザブルシリンジで吸引し、密封後室温にて6時間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド1.3 mL (10 v/w)で4回、次に2-プロパノール1.3 mL (10 v/w)で2回、続いてメタノール1.3 mL (10 v/w)で4回洗浄した後、終夜室温にて減圧乾燥し、0.178 gの乾燥樹脂 (化合物5)を得た。得られた樹脂を100 mLメスフラスコに21.6 mg秤量し、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液でメスアップし45分室温で振盪した。分光光度計を用いて溶液の吸光度からFmoc定量を行い、得られたFmoc定量値と乾燥樹脂の質量とLC A%から収率を算出した。
Eur. J. Org. Chem., 2013, 6372-6378に記載の反応条件でのFmoc-MeVal-MeAsp(OCTC)-pip (化合物5)の合成(レジンのアミノ酸に対し、Fmocアミノ酸:DIC:添加剤(K-Oxyma)=2:2:2の反応条件)
フィルター付きの5 mLディスポーザブルシリンジに乾燥樹脂(化合物4)を0.202 g (0.525 mmol/g, 0.105 mmol, 1.0 eq)秤量し、N,N-ジメチルホルムアミドを1.3 mL (10 v/w)加え30分間室温で静置させた。N,N-ジメチルホルムアミドを排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.1 mL (8 v/w)を加え室温で15分間振盪させた。反応溶液を排出後、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液を1.1 mL (8 v/w)再び加え室温で15分間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド 1.3 mL (10 v/w)で8回洗浄した。次にバイアルにFmoc-MeVal-OH 75 mg (0.21 mmol, 2.0 eq)とK-Oxyma 40 mg (0.21 mmol, 2.0 eq)を秤量し、N,N-ジメチルホルムアミドを0.54 mL (4 v/w)加え溶解させた。続いてDICを33 μl (0.21 mmol, 2.0 eq)バイアルに室温で加えた後、直ぐにこの溶液をディスポーザブルシリンジで吸引し、密封後室温にて6時間振盪させた。反応溶液を排出後、N,N-ジメチルホルムアミド1.3 mL (10 v/w)で4回、次に2-プロパノール1.3 mL (10 v/w)で2回、続いてメタノール1.3 mL (10 v/w)で4回洗浄した後、終夜室温にて減圧乾燥し、0.188 gの乾燥樹脂(化合物5)を得た。得られた樹脂を100 mLメスフラスコに21.0 mg秤量し、20%ピペリジンを含むN,N-ジメチルホルムアミド溶液でメスアップし45分室温で振盪した。分光光度計を用いて溶液の吸光度からFmoc定量を行い、得られたFmoc定量値と乾燥樹脂の質量とLC A%から収率を算出した。
縮合反応用の出発原料であるH-MeVal-MeAsp(OCTC)-pip (化合物14)は、本明細書に記載の担持、縮合、脱Fmoc条件を踏襲し合成した。1残基+1残基の縮合は実施例条件Aに準じ実施した。
縮合反応用の原料 (化合物14)のペプチド担持率は理論上0.63 mmol/gである。これは以下のように算出した。
1. Fmoc-MeAsp(OH)-pip (化合物3)をCTCレジンに担持した後の乾燥樹脂 (化合物4)のFmoc定量値を実施し、測定値は0.59 mmol/gであった。
2. この乾燥樹脂(化合物4) 1 gは、化合物3の分子量が436.51 (g/mol)であることを考慮すると、下式より0.258 gの化合物1と0.742 gの樹脂成分で構成される。
化合物3: 0.59 (mmol/g) x 1 (g) x 436.51 (g/mol) = 0.258 (g)。
樹脂成分: 1 (g) - 0.258 (g) = 0.742 (g)
3. 乾燥樹脂 (化合物4) 1 gから得られる縮合反応用の原料 (化合物14)の理論収量は、H-MeVal-MeAsp(OH)-pip (化合物15)質量が化合物3の物質量とペプチドの分子量に基づき算出可能であり、樹脂成分質量は反応前後で不変と考えると、
化合物14: 0.59 (mmol/g) x 1 (g) x 327.43 (g/mol) + 0.742 = 0.935 (g)
よって理論上の縮合反応用の原料(化合物14)のペプチド担持率は0.63 (mmol/g) (0.59 ÷ 0.935 = 0.63)となる。
Fmoc-cLeu-MeVal-MeAsp(OCTC)-pip (化合物16)の合成(実施例条件Aによる合成)
[縮合実験]
バイアルにFmoc-cLeu-OH 67 mg (0.19 mmol, 3.0 eq)とOxyma 13 mg (0.095 mmol, 1.5 eq)を秤量し、N,N-ジメチルホルムアミド0.80 mL (8 v/w)を加え、溶解させた。この溶液にDIC 59 μL (0.38 mmol, 6.0 eq)を加え、室温で2時間振盪させた。この反応溶液に乾燥樹脂(化合物14)を0.10 g (0.63 mmol/g, 0.063 mmol, 1.0 eq)加え、室温で24時間振盪させた。
[転換率確認実験]
もう一つのバイアルにFmoc-Gly-OH 62 mg (0.21 mmol, 3.3 eq)とOxyma 30 mg (0.21 mmol, 3.3 eq)を秤量し、N,N-ジメチルホルムアミド 0.40 mL (4 v/w)を加え、溶解させた。この溶液にDIC 65 μL (0.42 mmol, 6.6 eq)を加え、室温で1時間振盪させた。この溶液をFmoc-cLeu-OHの反応溶液へ移し、室温で2時間振盪させた。反応溶液をフィルター付きのディスポーザブルシリンジへ移し、反応溶液とレジンを濾別した。樹脂をN,N-ジメチルホルムアミド0.80 mL (8 v/w)、イソプロパノール0.80 mL (8 v/w)を用いて交互に2回ずつ洗浄後、N,N-ジメチルホルムアミド0.80 mL (8 v/w)で2回洗浄し、最後にMTBE 0.80 mL (8 v/w)で洗浄し、室温で通風乾燥させた。得られた乾燥樹脂(化合物16)を1% TFAのジクロロメタン溶液1 mLに浸して、脱樹脂反応を行った。
Gly-cap体(化合物17)と目的物(化合物18)のLC A%から、変換率を75% (68.9 ÷ (23.5 + 68.9)と算出した。
Chem. Eur. J., 2009, 15, 9404-9416に記載の反応条件でのFmoc-cLeu-MeVal-MeAsp(OCTC)-pip (化合物15)の合成(レジンのアミノ酸に対し、Fmocアミノ酸:縮合剤(COMU)=3:3の反応条件)
[縮合実験]
バイアルにFmoc-cLeu-OH 73 mg (0.21 mmol, 3.0 eq)とCOMU 89 mg (0.21 mmol, 3.0 eq)を秤量し、N,N-ジメチルホルムアミド0.80 mL (8 v/w)を加え、溶解させた。この溶液にN,N-ジイソプロピルエチルアミン73 μL (0.42 mmol, 6.0 eq)を加え、室温で30分間振盪させた。この反応溶液に乾燥樹脂(化合物14)を0.10 g (0.63 mmol/g, 0.063 mmol, 1.0 eq)加え、室温で16時間振盪させた。
[転換率確認実験]
もう一つのバイアルにFmoc-Gly-OH 62 mg (0.21 mmol, 3.3 eq)とOxyma 30 mg (0.21 mmol, 3.3 eq)を秤量し、N,N-ジメチルホルムアミド0.40 mL (4 v/w)を加え、溶解させた。この溶液にDIC 65 μL (0.42 mmol, 6.6 eq)を加え、室温で1時間振盪させた。この溶液をFmoc-cLeu-OHの反応溶液へ移し、室温で2時間振盪させた。反応溶液をフィルター付きのディスポーザブルシリンジへ移し、反応溶液とレジンを濾別した。樹脂をN,N-ジメチルホルムアミド 0.80 mL (8 v/w)、イソプロパノール0.80 mL (8 v/w)を用いて交互に2回ずつ洗浄後、N,N-ジメチルホルムアミド0.80 mL (8 v/w)で2回洗浄し、最後にMTBE 0.80 mL (8 v/w)で洗浄し、室温で通風乾燥させた。得られた乾燥樹脂(化合物16)を1% TFAのジクロロメタン溶液1 mLに浸して、脱樹脂反応を行った。
Gly-cap体(化合物17)と目的物(化合物18)のLC A%から、変換率を5.1% (4.7 ÷ (88.3 + 4.7)と算出した。
Claims (16)
- 第一のアミノ酸またはペプチドと、第二のアミノ酸またはペプチドとを、添加剤および縮合剤の存在下で縮合させて縮合体を得る工程を含む、ペプチド化合物を製造する方法であって、
添加剤のモル数が、第二のアミノ酸またはペプチドのモル数よりも少ない、前記方法。 - 第二のアミノ酸またはペプチドに対する添加剤のモル比が0.8以下である、請求項1に記載の方法。
- 第二のアミノ酸またはペプチドに対する縮合剤のモル比が1.0以上である、請求項1または2記載の方法。
- 第二のアミノ酸またはペプチドに対する縮合剤のモル比が1.2~4.0である、請求項1~3のいずれか一項に記載の方法。
- 第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比が10以下である、請求項1~4のいずれか一項に記載の方法。
- 第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比が1~2であって、第二のアミノ酸またはペプチドに対する添加剤のモル比が0.7以下である、請求項1~5のいずれか一項に記載の方法。
- 第一のアミノ酸またはペプチドに対する第二のアミノ酸またはペプチドのモル比(第1のモル比)が2以上であって、第二のアミノ酸またはペプチドに対する添加剤のモル比が、第1のモル比-1以下である、請求項1~6のいずれか一項に記載の方法。
- 第一のアミノ酸またはペプチドに対する添加剤のモル比が2.0以下である、請求項1~7のいずれか一項に記載の方法。
- 第一のアミノ酸またはペプチドに対する縮合剤のモル比が1.3以上である、請求項1~8のいずれか一項に記載の方法。
- 添加剤が、Oxyma、HOBt、HOOBt、またはHOAtである、請求項1~9のいずれか一項に記載の方法。
- 縮合剤が、DIC、DCC、EDCI、またはEDCI・HClである、請求項1~10のいずれか一項に記載の方法。
- 前記ペプチド化合物が前記縮合体であるか、あるいは、前記ペプチド化合物がその構造中に前記縮合体を含む、請求項1~11のいずれか一項に記載の方法。
- 第一のアミノ酸、または第一のペプチドのN末端のアミノ酸、および/もしくは第一のペプチドのC末端のアミノ酸が、N-アルキルアミノ酸である、請求項1~12のいずれか一項に記載の方法。
- 第一のアミノ酸、または第一のペプチドのC末端のアミノ酸が、N-アルキルβアミノ酸である、請求項13に記載の方法。
- 第二のアミノ酸、または第二のペプチドのC末端のアミノ酸が、α,α-ジ置換アミノ酸、β-分岐アミノ酸、またはN-アルキルアミノ酸である、請求項1~14のいずれか一項に記載の方法。
- 請求項1~15のいずれか一項に記載の方法によってペプチド化合物を得る工程、および
該ペプチド化合物を環化する工程
を含む、環状ペプチド化合物の製造方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180039631.2A CN115698032A (zh) | 2020-06-03 | 2021-06-03 | 困难序列的高效的肽缩合法 |
JP2022528885A JPWO2021246471A1 (ja) | 2020-06-03 | 2021-06-03 | |
EP21818327.5A EP4144747A4 (en) | 2020-06-03 | 2021-06-03 | EFFICIENT PEPTIDE CONDENSATION PROCESS FOR DIFFICULT SEQUENCES |
KR1020227044622A KR20230019120A (ko) | 2020-06-03 | 2021-06-03 | 고난도 서열의 효율적 펩티드 축합법 |
US17/928,759 US20230295221A1 (en) | 2020-06-03 | 2021-06-03 | Efficient peptide condensation method for difficult sequences |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020096801 | 2020-06-03 | ||
JP2020-096801 | 2020-06-03 | ||
JP2020217156 | 2020-12-25 | ||
JP2020-217156 | 2020-12-25 | ||
JP2021078394 | 2021-05-06 | ||
JP2021-078394 | 2021-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021246471A1 true WO2021246471A1 (ja) | 2021-12-09 |
Family
ID=78831238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/021125 WO2021246471A1 (ja) | 2020-06-03 | 2021-06-03 | 高難度配列の効率的ペプチド縮合法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230295221A1 (ja) |
EP (1) | EP4144747A4 (ja) |
JP (1) | JPWO2021246471A1 (ja) |
KR (1) | KR20230019120A (ja) |
CN (1) | CN115698032A (ja) |
TW (1) | TW202210498A (ja) |
WO (1) | WO2021246471A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001514659A (ja) * | 1997-03-13 | 2001-09-11 | ビーエーエスエフ アクチェンゲゼルシャフト | ドラスタチン−15誘導体とタキサンとの併用 |
JP2018070590A (ja) * | 2016-09-02 | 2018-05-10 | シーイーエム・コーポレーション | 高温でのペプチド合成のための過剰カルボジイミドの使用 |
WO2018225864A1 (ja) | 2017-06-09 | 2018-12-13 | 中外製薬株式会社 | 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ |
WO2018225851A1 (ja) * | 2017-06-09 | 2018-12-13 | 中外製薬株式会社 | N-置換アミノ酸を含むペプチドの合成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999026964A1 (en) * | 1997-11-20 | 1999-06-03 | Ortho-Mcneil Pharmaceutical, Inc. | LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES |
WO2011006644A2 (en) | 2009-07-15 | 2011-01-20 | Lonza Ltd | Process for the production of exenatide and of an exenatide analogue |
TWI640541B (zh) | 2011-12-28 | 2018-11-11 | 中外製藥股份有限公司 | Peptide compound having an annular portion and pharmaceutical composition thereof |
CN106795201A (zh) | 2014-04-03 | 2017-05-31 | 美国安进公司 | 用于制备amg416的方法 |
US10125163B2 (en) | 2015-10-23 | 2018-11-13 | Cem Corporation | Solid phase peptide synthesis |
JP7411414B2 (ja) | 2017-12-15 | 2024-01-11 | 中外製薬株式会社 | ペプチドの製造方法、及び塩基の処理方法 |
-
2021
- 2021-06-03 KR KR1020227044622A patent/KR20230019120A/ko active Search and Examination
- 2021-06-03 CN CN202180039631.2A patent/CN115698032A/zh active Pending
- 2021-06-03 EP EP21818327.5A patent/EP4144747A4/en active Pending
- 2021-06-03 TW TW110120180A patent/TW202210498A/zh unknown
- 2021-06-03 JP JP2022528885A patent/JPWO2021246471A1/ja active Pending
- 2021-06-03 US US17/928,759 patent/US20230295221A1/en active Pending
- 2021-06-03 WO PCT/JP2021/021125 patent/WO2021246471A1/ja unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001514659A (ja) * | 1997-03-13 | 2001-09-11 | ビーエーエスエフ アクチェンゲゼルシャフト | ドラスタチン−15誘導体とタキサンとの併用 |
JP2018070590A (ja) * | 2016-09-02 | 2018-05-10 | シーイーエム・コーポレーション | 高温でのペプチド合成のための過剰カルボジイミドの使用 |
WO2018225864A1 (ja) | 2017-06-09 | 2018-12-13 | 中外製薬株式会社 | 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ |
WO2018225851A1 (ja) * | 2017-06-09 | 2018-12-13 | 中外製薬株式会社 | N-置換アミノ酸を含むペプチドの合成方法 |
Non-Patent Citations (13)
Title |
---|
"Side reactions in Peptide Synthesis", 2015, ACADEMIC PRESS, pages: 1 - 31 |
ACC CHEM. RES., vol. 41, 2008, pages 1331 - 1342 |
ACS COMB. SCI., vol. 15, 2013, pages 229 - 234 |
AMINO ACIDS, PEPTIDES AND PROTEINS IN ORGANIC CHEMISTRY: BUILDING BLOCKS, CATALYSIS AND COUPLING CHEMISTRY, vol. 3, 2011 |
AMINO ACIDS, vol. 50, 2018, pages 39 - 68 |
ANGEW. CHEM. INT. ED., vol. 52, 2013, pages 254 - 269 |
CHEM. EUR. J., vol. 15, 2009, pages 9404 - 9416 |
EUR. J. ORG. CHEM., 2013, pages 6372 - 6378 |
FUTURE MED. CHEM., vol. 1, 2009, pages 1289 - 1310 |
GREEN. CHEM., vol. 21, 2019, pages 2594 - 2600 |
GREENE'S: "Protective Groups in Organic Synthesis", 2014, JOHN WILEY & SONS |
NOZAKI, S.: "Delay of coupling caused by excess additive s", JOURNAL OF PEPTIDE SCIENCE, vol. 12, 2006, pages 147 - 153, XP055436857, DOI: https://doi.org/10.1002/psc.689 * |
See also references of EP4144747A4 |
Also Published As
Publication number | Publication date |
---|---|
TW202210498A (zh) | 2022-03-16 |
EP4144747A4 (en) | 2024-05-29 |
KR20230019120A (ko) | 2023-02-07 |
EP4144747A1 (en) | 2023-03-08 |
US20230295221A1 (en) | 2023-09-21 |
JPWO2021246471A1 (ja) | 2021-12-09 |
CN115698032A (zh) | 2023-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7229158B2 (ja) | N-置換アミノ酸を含むペプチドの合成方法 | |
US7202332B2 (en) | Methods for preparing internally constrained peptides and peptidomimetics | |
JP3231045B2 (ja) | 固体支持体上でのポリピロール及びポリイミダゾールカルボキサミドの合成方法 | |
US20130123196A1 (en) | Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics | |
JP5199126B2 (ja) | グルカゴン様ペプチドの合成 | |
WO2022234853A1 (ja) | Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物 | |
JP2021519347A (ja) | ペプチドミメティクスのマクロサイクリック化 | |
WO2022234864A1 (ja) | N-置換アミノ酸残基を含む環状化合物の製造方法 | |
JP2019527672A (ja) | 多様な大環状化合物のライブラリならびにその製造方法および使用方法 | |
WO2022138891A1 (ja) | N-置換-アミノ酸残基を含むペプチド化合物の製造方法 | |
WO2018227053A1 (en) | Non-chromatographic purification of macrocyclic peptides by a resin catch and release | |
US8895739B2 (en) | Acylation of hindered amines and functionalized bis-peptides obtained thereby | |
WO2021246471A1 (ja) | 高難度配列の効率的ペプチド縮合法 | |
Hiebl et al. | Large‐scale synthesis of hematoregulatory nonapeptide SK&F 107647 by fragment coupling | |
JP7165289B1 (ja) | N-置換アミノ酸残基を含む環状化合物の製造方法 | |
CN111995663B (zh) | 一种含有N-氨基咪唑烷-2-酮结构的Ang-(1-7)多肽类似物 | |
JP7430297B2 (ja) | N-アルキルアミノ酸、およびn-アルキルアミノ酸を含むペプチドの製造方法 | |
Prabhakaran et al. | Large Scale Synthesis of Native Turn and Helix Mimics Stabilized by a Generic Hydrogen Bond Surrogate | |
EP4249496A1 (en) | Method for supporting amino acid on resin for solid-phase synthesis | |
Strowes | Towards the synthesis of a protein β-turn mimetic based on the opioid pentapeptide leu-enkephalin | |
CN109897091A (zh) | 一种含非天然氨基酸的环状抗菌肽及其制备方法和应用 | |
TW202302620A (zh) | 胺基酸或肽之製造方法、保護基形成用試藥及化合物 | |
Kil | Design & Synthesis of Peptidomimetics Adopting Secondary Structures for Inhibition of p53/MDM2 Protein-protein Interaction and Multiple Myeloma Cell Adhesion | |
Nardone | Synthesis, Structure and Properties of Cyclopeptoids and Cyclopeptides | |
Lindman | Design and synthesis of-turn peptidomimetics: Applications to angiotensin II |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21818327 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022528885 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021818327 Country of ref document: EP Effective date: 20221128 |
|
ENP | Entry into the national phase |
Ref document number: 20227044622 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |